TREATMENT READING
Non-Small Cell Lung Cancer
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
230 sections
- Treatment Option Overview for NSCLC
- Treatment of Occult NSCLC
- Treatment Options for Occult NSCLC
- Treatment of Stage 0 NSCLC
- Treatment Options for Stage 0 NSCLC
- Surgery
- Endobronchial therapies
- Treatment of Stages IA and IB NSCLC
- Treatment Options for Stages IA and IB NSCLC
- Surgery
- Adjuvant therapy
- Adjuvant chemotherapy
- Adjuvant targeted therapy (for patients with stage IB NSCLC and EGFR variants)
- Adjuvant targeted therapy (for patients with stage IB tumors and ALK variants)
- Adjuvant immunotherapy
- Adjuvant external radiation therapy
- Adjuvant brachytherapy
- Radiation therapy
- Conventional radiation therapy
- Hypofractionated radiation therapy
- Stereotactic body radiation therapy (SBRT)
- Treatment of Stages IIA and IIB NSCLC
- Treatment Options for Stages IIA and IIB NSCLC
- Surgery with or without adjuvant or neoadjuvant therapy
- Surgery alone
- Adjuvant chemotherapy
- Adjuvant targeted therapy (for patients with EGFR variants)
- Adjuvant targeted therapy (for patients with ALK variants)
- Adjuvant immunotherapy
- Adjuvant radiation therapy
- Neoadjuvant chemotherapy
- Neoadjuvant immunotherapy with chemotherapy
- Nivolumab plus platinum-based chemotherapy
- Perioperative (neoadjuvant and adjuvant) immunotherapy with chemotherapy
- Perioperative pembrolizumab plus platinum-based chemotherapy
- Perioperative durvalumab plus platinum-based chemotherapy
- Perioperative nivolumab plus platinum-based chemotherapy
- Perioperative toripalimab plus platinum-based chemotherapy
- Radiation therapy
- Treatment of Stage IIIA NSCLC
- Treatment Options for Resected/Resectable Stage IIIA NSCLC
- Surgery
- Neoadjuvant therapy
- Neoadjuvant chemotherapy
- Neoadjuvant chemoradiation therapy
- Neoadjuvant immunotherapy with chemotherapy
- Nivolumab plus platinum-based chemotherapy
- Perioperative (neoadjuvant and adjuvant) immunotherapy with chemotherapy
- Perioperative pembrolizumab plus platinum-based chemotherapy
- Perioperative durvalumab plus platinum-based chemotherapy
- Perioperative nivolumab plus platinum-based chemotherapy
- Perioperative toripalimab plus platinum-based chemotherapy
- Adjuvant therapy
- Adjuvant chemotherapy
- Adjuvant targeted therapy (for patients with EGFR variants)
- Adjuvant targeted therapy (for patients with ALK variants)
- Adjuvant immunotherapy
- Adjuvant chemoradiation therapy
- Adjuvant radiation therapy
- Treatment Options for Unresectable Stage IIIA NSCLC
- Chemoradiation therapy
- Concurrent versus sequential chemoradiation therapy
- Radiation therapy dose escalation for concurrent chemoradiation
- Consolidation therapy following concurrent chemoradiation
- Consolidation immunotherapy
- Durvalumab
- Osimertinib (for patients with EGFR variants)
- Other systemic consolidation therapies
- Radiation therapy
- Locally advanced unresectable tumors
- Palliative treatment
- Treatment Options for Superior Sulcus Tumors
- Surgery
- Chemoradiation therapy followed by surgery
- Radiation therapy dose escalation for concurrent chemoradiation
- Radiation therapy alone
- Treatment Options for Tumors That Invade the Chest Wall
- Treatment of Stages IIIB and IIIC NSCLC
- Treatment Options for Stages IIIB and IIIC NSCLC
- Sequential or concurrent chemotherapy and radiation therapy
- Radiation therapy dose escalation for concurrent chemoradiation
- Systemic consolidation therapy before or after concurrent chemoradiation therapy
- Consolidation immunotherapy
- Durvalumab
- Osimertinib (for patients with EGFR variants)
- Other systemic consolidation therapies
- Radiation therapy alone
- For treatment of locally advanced unresectable tumor in patients who are not candidates for chemotherapy
- For patients requiring palliative treatment
- Treatment of Newly Diagnosed Stage IV, Relapsed, and Recurrent NSCLC
- Factors Affecting Treatment Selection
- History and molecular features
- Age and comorbidity
- Performance status
- Treatment Options for Newly Diagnosed Stage IV, Relapsed, and Recurrent NSCLC (First-Line Therapy)
- Cytotoxic combination chemotherapy
- Combination chemotherapy
- Drug and dose schedule
- Combination chemotherapy with monoclonal antibodies
- Bevacizumab
- Cetuximab
- Necitumumab
- Maintenance therapy after first-line chemotherapy (for patients with stable or responding disease after four cycles of platinum-based combination chemotherapy)
- EGFR tyrosine kinase inhibitors (TKIs) with or without chemotherapy (for patients with EGFR variants)
- Osimertinib alone
- Osimertinib plus chemotherapy
- Amivantamab plus lazertinib
- Dacomitinib
- Gefitinib
- Erlotinib
- Afatinib
- EGFR-directed therapy (for patients with EGFR exon 20 insertions)
- Amivantamab
- ALK inhibitors (for patients with ALK translocations)
- Alectinib
- Lorlatinib
- Crizotinib
- Ceritinib
- Brigatinib
- BRAF V600E and MEK inhibitors (for patients with BRAF V600E variants)
- Dabrafenib and trametinib
- ROS1 inhibitors (for patients with ROS1 rearrangements)
- Entrectinib
- Crizotinib
- Repotrectinib (for both ROS1 TKI-naïve and ROS1 TKI-treated patients)
- NTRK inhibitors (for patients with NTRK fusions)
- Larotrectinib
- Entrectinib
- RET inhibitors (for patients with RET fusions)
- Selpercatinib
- Pralsetinib
- MET inhibitors (for patients with MET exon 14-skipping variants)
- Tepotinib
- Capmatinib
- Immune checkpoint inhibitors with or without chemotherapy
- Pembrolizumab plus chemotherapy
- Pembrolizumab alone
- Cemiplimab-rwlc plus chemotherapy
- Cemiplimab-rwlc alone
- Tremelimumab
- Durvalumab plus tremelimumab plus chemotherapy
- Atezolizumab alone
- Atezolizumab plus chemotherapy
- Atezolizumab plus bevacizumab plus chemotherapy
- Nivolumab plus ipilimumab
- mTOR inhibitors
- Everolimus
- Local therapies and special considerations
- Endobronchial laser therapy and/or brachytherapy (for obstruction lesions)
- EBRT (primarily for palliation of local symptomatic tumor growth)
- Treatment of second primary tumor
- Treatment of brain metastases
- Treatment of Progressive Stage IV, Relapsed, and Recurrent NSCLC
- Treatment Options for Progressive Stage IV, Relapsed, and Recurrent NSCLC (Second-Line Therapy)
- Chemotherapy
- Docetaxel
- Docetaxel plus ramucirumab
- Datopotamab deruxtecan
- Pemetrexed
- EGFR-directed therapy
- EGFR-directed therapy after first-line chemotherapy (for patients with EGFR-sensitizing variants)
- Erlotinib
- Gefitinib
- Afatinib
- EGFR-directed therapy (for patients with acquired EGFR T790M variants after previous EGFR-directed therapy)
- Osimertinib
- EGFR-directed therapy after first-line chemotherapy (for patients with EGFR exon 20 insertions)
- Amivantamab
- Amivantamab plus chemotherapy
- Subcutaneous amivantamab-lazertinib
- ALK-directed TKIs
- ALK-directed TKIs after first-line chemotherapy
- Crizotinib
- ALK-directed TKIs after prior ALK TKI therapy
- Ceritinib
- Alectinib
- Brigatinib
- Lorlatinib
- BRAF V600E and MEK inhibitors (for patients with BRAF V600E variants)
- Dabrafenib and trametinib
- ROS1-directed therapy
- Entrectinib
- Crizotinib
- Repotrectinib (for both ROS1 TKI-naïve and ROS1 TKI-treated patients)
- NTRK inhibitors (for patients with NTRK fusions)
- Larotrectinib
- Entrectinib
- RET inhibitors (for patients with RET fusions)
- Selpercatinib
- Pralsetinib
- MET inhibitors (for patients with MET exon 14-skipping variants)
- Tepotinib
- Capmatinib
- KRAS G12C inhibitors (for patients with KRAS G12C variants)
- Adagrasib
- Sotorasib
- HER2-targeted therapy (for patients with HER2 variants)
- Trastuzumab deruxtecan
- Immunotherapy
- Nivolumab
- Pembrolizumab
- Atezolizumab
- mTOR inhibitors
- Everolimus
- Certain factors affect the prognosis (chance of recovery) and treatment options.
- Non-small cell lung cancer can recur (come back) after it has been treated.
- Treatment Option Overview
- Key Points
- There are different types of treatment for people with non-small cell lung cancer.
- The following types of treatment are used:
- Surgery
- Radiation therapy
- Chemotherapy
- Targeted therapy
- Immunotherapy
- Laser therapy
- Photodynamic therapy (PDT)
- Cryosurgery
- Electrocautery
- New types of treatment are being tested in clinical trials.
- Treatment for non-small cell lung cancer may cause side effects.
- Follow-up care may be needed.
- Treatment of Occult Non-Small Cell Lung Cancer
- Treatment of Stage 0 (carcinoma in situ)
- Treatment of Stage I Non-Small Cell Lung Cancer
- Treatment of Stage II Non-Small Cell Lung Cancer
- Treatment of Stage IIIA Non-Small Cell Lung Cancer
- Treatment of Stage IIIB and Stage IIIC Non-Small Cell Lung Cancer
- Treatment of Newly Diagnosed Stage IV, Relapsed, and Recurrent Non-Small Cell Lung Cancer
- Treatment of Progressive Stage IV, Relapsed, and Recurrent Non-Small Cell Lung Cancer
Treatment Option Overview for NSCLC
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
In non-small cell lung cancer (NSCLC), results of standard treatment are poor except for the most localized cancers. All newly diagnosed patients with NSCLC are potential candidates for studies evaluating new forms of treatment.
Treatment decisions are based on some of the following factors:
Knowledge of histological type and molecular features.
Tumor size and location.
Involvement of pleura.
Surgical margins.
Status and location of lymph nodes by station.
Tumor grade.
Lymphovascular invasion.
Surgery is potentially the most curative therapeutic option for this disease. Postoperative chemotherapy may provide an additional benefit to patients with resected NSCLC. Radiation therapy combined with chemotherapy can produce a cure in a small number of patients and can provide palliation in most patients. Prophylactic cranial irradiation may reduce the incidence of brain metastases, but there is no evidence of a survival benefit and the effect of prophylactic cranial irradiation on quality of life is not known.[1,2] In patients with advanced-stage disease, chemotherapy or EGFR kinase inhibitors offer modest improvements in median survival, although overall survival is poor.[3,4]
Chemotherapy has produced short-term improvement in disease-related symptoms in patients with advanced NSCLC. Several clinical trials have attempted to assess the impact of chemotherapy on tumor-related symptoms and quality of life. In total, these studies suggest that tumor-related symptoms may be controlled by chemotherapy without adversely affecting overall quality of life;[5,6] however, the impact of chemotherapy on quality of life requires more study. In general, medically eligible older patients with good performance status obtain the same benefits from treatment as younger patients.
The identification of pathogenic variants has led to the development of molecularly targeted therapies for lung cancer that have improved the survival of some patients with metastatic disease.[7] In particular, genetic abnormalities in EGFR, MAPK, and PI3K signaling pathways in subsets of NSCLC may affect drug sensitivity and primary or acquired resistance to kinase inhibitors. EGFR variants strongly predict the improved response rate and progression-free survival in patients who receive EGFR inhibitors. ALK::EML4 fusion genes and other genes form translocation products that occur in 3% to 7% of unselected NSCLC cases and are responsive to pharmacological inhibition of ALK by agents like alectinib. The MET oncogene encodes hepatocyte growth factor receptor. Amplification of this gene has been associated with secondary resistance to EGFR tyrosine kinase inhibitors. Recurrent fusions involving the ROS1 gene are observed in up to 2% of NSCLCs and are responsive to treatment with crizotinib and entrectinib. NTRK gene fusions can occur in up to 1% of NSCLCs and can be treated with the TRK inhibitors, larotrectinib and entrectinib. For more information, see the Molecular Features section.
Sources: 7 · Molecular Features
The treatment options for each stage of NSCLC are presented in Table 5.
Sources: Table 5
| Stage (TNM Definitions) | Treatment Options | |
|---|---|---|
| NSCLC = non-small cell lung cancer; TKIs = tyrosine kinase inhibitors; TNM = tumor, node, metastasis. | ||
| Occult NSCLC | Surgery | |
| Stage 0 NSCLC | Surgery | |
| Endobronchial therapies | ||
| Stages IA and IB NSCLC | Surgery | |
| Adjuvant therapy | ||
| Radiation therapy | ||
| Stages IIA and IIB NSCLC | Surgery with or without adjuvant and/or neoadjuvant therapy | |
| Radiation therapy | ||
| Stage IIIA NSCLC | Resected or resectable disease | Surgery with neoadjuvant and/or adjuvant therapy |
| Neoadjuvant therapy | ||
| Perioperative (neoadjuvant and adjuvant) immunotherapy with chemotherapy | ||
| Adjuvant therapy | ||
| Unresectable disease | Chemoradiation therapy | |
| Radiation therapy | ||
| Superior sulcus tumors | Surgery | |
| Chemoradiation therapy followed by surgery | ||
| Radiation therapy alone | ||
| Tumors that invade the chest wall | Surgery | |
| Surgery and radiation therapy | ||
| Radiation therapy alone | ||
| Chemotherapy combined with radiation therapy and/or surgery | ||
| Stages IIIB and IIIC NSCLC | Sequential or concurrent chemotherapy and radiation therapy | |
| Radiation therapy alone | ||
| Newly Diagnosed Stage IV, Relapsed, and Recurrent NSCLC | Cytotoxic combination chemotherapy | |
| Combination chemotherapy with monoclonal antibodies | ||
| Maintenance therapy after first-line chemotherapy (for patients with stable or responding disease after four cycles of platinum-based combination chemotherapy) | ||
| EGFR TKIs with or without chemotherapy (for patients with EGFR variants) | ||
| EGFR-directed therapy (for patients with EGFR exon 20 insertions) | ||
| ALK inhibitors (for patients with ALK translocations) | ||
| BRAF V600E and MEK inhibitors (for patients with BRAF V600E variants) | ||
| ROS1 inhibitors (for patients with ROS1 rearrangements) | ||
| NTRK inhibitors (for patients with NTRK fusions) | ||
| RET inhibitors (for patients with RET fusions) | ||
| MET inhibitors (for patients with MET exon 14-skipping variants) | ||
| Immune checkpoint inhibitors with or without chemotherapy | ||
| mTOR inhibitors (for patients with unresectable, locally advanced or metastatic, progressive, well-differentiated, nonfunctional, neuroendocrine tumors) | ||
| Local therapies and special considerations | ||
| Progressive Stage IV, Relapsed, and Recurrent NSCLC | Chemotherapy | |
| EGFR-directed therapy | ||
| ALK-directed TKIs | ||
| BRAF V600E and MEK inhibitors (for patients with BRAF V600E variants) | ||
| ROS1-directed therapy | ||
| NTRK inhibitors (for patients with NTRK fusions) | ||
| RET inhibitors (for patients with RET fusions) | ||
| MET inhibitors (for patients with MET exon 14-skipping variants) | ||
| KRAS G12C inhibitors (for patients with KRAS G12C variants) | ||
| HER2-targeted therapy (for patients with HER2 variants) | ||
| Immunotherapy | ||
| mTOR inhibitors (for patients with unresectable, locally advanced or metastatic, progressive, well-differentiated, nonfunctional, neuroendocrine tumors) | ||
Sources: TNM Definitions · Surgery · Surgery · Endobronchial therapies · Surgery · Adjuvant therapy · Radiation therapy · Surgery with or without adjuvant and/or neoadjuvant therapy · Radiation therapy · Surgery with neoadjuvant and/or adjuvant therapy · Neoadjuvant therapy · Perioperative (neoadjuvant and adjuvant) immunotherapy with chemotherapy · Adjuvant therapy · Chemoradiation therapy · Radiation therapy · Surgery · Chemoradiation therapy followed by surgery · Radiation therapy alone · Surgery · Surgery and radiation therapy · Radiation therapy alone · Chemotherapy combined with radiation therapy and/or surgery · Sequential or concurrent chemotherapy and radiation therapy · Radiation therapy alone · Cytotoxic combination chemotherapy · Combination chemotherapy with monoclonal antibodies · Maintenance therapy after first-line chemotherapy · EGFR TKIs with or without chemotherapy · EGFR-directed therapy · ALK inhibitors · BRAF V600E and MEK inhibitors · ROS1 inhibitors · NTRK inhibitors · RET inhibitors · MET inhibitors · Immune checkpoint inhibitors with or without chemotherapy · mTOR inhibitors · Local therapies and special considerations · Chemotherapy · EGFR-directed therapy · ALK-directed TKIs · BRAF V600E and MEK inhibitors · ROS1-directed therapy · NTRK inhibitors · RET inhibitors · MET inhibitors · KRAS G12C inhibitors · HER2-targeted therapy · Immunotherapy · mTOR inhibitors
In addition to the treatment options presented in Table 5, treatment options under clinical evaluation include:
Combining local treatment (surgery).
Regional treatment (radiation therapy).
Systemic treatments (chemotherapy, immunotherapy, and targeted agents).
Developing more effective systemic therapy.
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Treatment of Occult NSCLC
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
In occult lung cancer, a diagnostic evaluation often includes chest x-ray and selective bronchoscopy with close follow-up (e.g., computed tomography scan), when needed, to define the site and nature of the primary tumor; tumors discovered in this fashion are generally early stage and curable by surgery.
After discovery of the primary tumor, treatment involves establishing the stage of the tumor. Therapy is identical to that recommended for other non-small cell lung cancer (NSCLC) patients with similar-stage disease.
Treatment Options for Occult NSCLC
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Treatment options for occult NSCLC include:
Sources: occult NSCLC
Surgery.
Treatment of Stage 0 NSCLC
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Treatment Options for Stage 0 NSCLC
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Treatment options for stage 0 NSCLC include:
Sources: stage 0 NSCLC
Surgery.
Sources: Surgery
Endobronchial therapies, including photodynamic therapy, electrocautery, cryotherapy, and neodymium-doped yttrium aluminum garnet (Nd-YAG) laser therapy.
Sources: Endobronchial therapies
Surgery
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Segmentectomy or wedge resection are used to preserve maximum normal pulmonary tissue because patients with stage 0 NSCLC are at a high risk of second lung cancers. Because these tumors are, by definition, noninvasive and incapable of metastasizing, they should be curable with surgical resection; however, such lesions, when identified, are often centrally located and may require a lobectomy.
Endobronchial therapies
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Patients with central lesions may be candidates for curative endobronchial therapy. Endobronchial therapies that preserve lung function include photodynamic therapy, electrocautery, cryotherapy, and Nd-YAG laser therapy.[3-6]
Evidence (endobronchial therapies):
Small case series have reported high complete response rates and long-term survival in selected patients.[7,8][Level of evidence C2]
Sources: 7 · 8 · Level of evidence C2
Efficacy of these treatment modalities in the management of patients with early NSCLC remains to be proven in definitive randomized controlled trials.
Treatment of Stages IA and IB NSCLC
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Treatment Options for Stages IA and IB NSCLC
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Treatment options for stages IA non-small cell lung cancer (NSCLC) and IB NSCLC include:
Sources: stages IA non-small cell lung cancer (NSCLC) · IB NSCLC
Surgery.
Sources: Surgery
Adjuvant therapy.
Sources: Adjuvant therapy
Adjuvant therapy.
Adjuvant chemotherapy (for patients with large stage IB tumors).
Sources: Adjuvant chemotherapy
Adjuvant targeted therapy (for patients with stage IB tumors and EGFR variants).
Sources: Adjuvant targeted therapy
Adjuvant targeted therapy (for patients with stage IB tumors and ALK variants).
Sources: Adjuvant targeted therapy
Adjuvant immunotherapy (for patients with stage IB tumors >4 cm).
Sources: Adjuvant immunotherapy
Radiation therapy (for patients who cannot have surgery or choose not to have surgery).
Sources: Radiation therapy
Chemotherapy and radiation therapy have not been shown to improve survival in patients with stage I NSCLC that has been completely resected.
Surgery
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Surgery is the treatment of choice for patients with stage I NSCLC. A lobectomy or segmental, wedge, or sleeve resection may be performed as appropriate. Patients with impaired pulmonary function are candidates for segmental or wedge resection of the primary tumor. Careful preoperative assessment of the patient’s overall medical condition, especially the patient’s pulmonary reserve, is critical in considering the benefits of surgery. The immediate postoperative mortality rate is age related, but a 3% to 5% mortality rate with lobectomy can be expected.[1]
Sources: 1
Evidence (surgery):
The Lung Cancer Study Group conducted a randomized study (LCSG-821) that compared lobectomy with limited resection for patients with stage I lung cancer. Results of the study showed:[2]
Sources: 2
The Lung Cancer Study Group conducted a randomized study (LCSG-821) that compared lobectomy with limited resection for patients with stage I lung cancer. Results of the study showed:[2]
A reduction in local recurrence for patients treated with lobectomy compared with those treated with limited excision.
No significant difference in overall survival (OS).
Similar results were reported from a nonrandomized comparison of anatomical segmentectomy and lobectomy.[3]
Sources: 3
Similar results were reported from a nonrandomized comparison of anatomical segmentectomy and lobectomy.[3]
A survival advantage was noted with lobectomy for patients with tumors larger than 3 cm but not for those with tumors smaller than 3 cm.
The rate of locoregional recurrence was significantly less after lobectomy, regardless of primary tumor size.
A study of stage I patients showed:[4]
Sources: 4
A study of stage I patients showed:[4]
Those treated with wedge or segmental resections had a local recurrence rate of 50% (i.e., 31 recurrences out of 62 patients) despite having undergone complete resections.[4]
Sources: 4
A multicenter, noninferiority, phase III trial (NCT00499330) evaluated lobar or sublobar resection in patients with peripheral stage IA NSCLC. A total of 697 patients with clinical stage T1a, N0 tumors (tumor size <2 cm) were randomly assigned to undergo sublobar resection or lobar resection after intraoperative confirmation of node-negative disease in the hilar and mediastinal lymph nodes. The primary end point was disease-free survival (DFS).[5][Level of evidence B1]These results suggest that sublobar resection by anatomical segmentectomy or wedge resection is effective for management of clinical stage T1a, N0 NSCLC when intraoperative sampling of hilar and mediastinal lymph nodes is negative.
Sources: NCT00499330 · 5 · Level of evidence B1
A multicenter, noninferiority, phase III trial (NCT00499330) evaluated lobar or sublobar resection in patients with peripheral stage IA NSCLC. A total of 697 patients with clinical stage T1a, N0 tumors (tumor size <2 cm) were randomly assigned to undergo sublobar resection or lobar resection after intraoperative confirmation of node-negative disease in the hilar and mediastinal lymph nodes. The primary end point was disease-free survival (DFS).[5][Level of evidence B1]These results suggest that sublobar resection by anatomical segmentectomy or wedge resection is effective for management of clinical stage T1a, N0 NSCLC when intraoperative sampling of hilar and mediastinal lymph nodes is negative.
After a median follow-up of 7 years, sublobar resection was noninferior to lobar resection for DFS (hazard ratio [HR], 1.01; 90% confidence interval [CI], 0.83–1.24; one-sided P = .02 for noninferiority).
OS was similar after sublobar resection or lobar resection (HR, 0.95; 95% CI, 0.72–1.26).
No substantial differences were noted in the incidence of locoregional or distant disease recurrence between the two groups.
At 6 months after surgery, the magnitude of reduction from baseline in the percentage of predicted FEV1 (forced expiratory volume in first second of expiration) was greater in the lobectomy group (-6%; 95% CI, -8% to -5%) versus the sublobar resection group (-4%; 95% CI, -5% to -2%). The magnitude of reduction in the percentage of predicted FVC (forced vital capacity) was also greater after lobectomy (-5%; 95% CI, -7% to -3%) than after sublobar resection (-3%; 95% CI, -4% to -1%).
The Cochrane Collaboration reviewed 11 randomized trials with a total of 1,910 patients who underwent surgical interventions for early-stage (I–IIIA) lung cancer.[6] A pooled analysis of three trials reported the following:
Sources: 6
The Cochrane Collaboration reviewed 11 randomized trials with a total of 1,910 patients who underwent surgical interventions for early-stage (I–IIIA) lung cancer.[6] A pooled analysis of three trials reported the following:
Four-year survival was superior in patients with resectable stage I, II, or IIIA NSCLC who underwent resection and complete ipsilateral mediastinal lymph node dissection (CMLND), compared with those who underwent resection and lymph node sampling; the HR was estimated to be 0.78 (95% CI, 0.65–0.93, P = .005).[6][Level of evidence A1]
Sources: 6 · Level of evidence A1
There was a significant reduction in any cancer recurrence (local or distant) in the CMLND group (relative risk [RR], 0.79; 95% CI, 0.66–0.95; P = .01) that appeared mainly because of a reduction in the number of distant recurrences (RR, 0.78; 95% CI, 0.61–1.00; P = .05).
There was no difference in operative mortality.
Air leak lasting more than 5 days was significantly more common in patients assigned to CMLND (RR, 2.94; 95% CI, 1.01–8.54; P = .05).
CMLND versus lymph node sampling was evaluated in a large, randomized, phase III trial (ACOSOG-Z0030 [NCT00003831]).[7,8]
Sources: ACOSOG-Z0030 · 7 · 8
CMLND versus lymph node sampling was evaluated in a large, randomized, phase III trial (ACOSOG-Z0030 [NCT00003831]).[7,8]
Preliminary analyses of operative morbidity and mortality showed comparable rates from the procedures.[7,8]
There was no difference in OS, DFS, local recurrence, and regional recurrence.[8][Level of evidence A1]
Sources: 8 · Level of evidence A1
Current evidence suggests that lung cancer resection combined with CMLND is not associated with improvement in survival compared with lung cancer resection combined with systematic sampling of mediastinal lymph nodes in patients with stage I, II, or IIIA NSCLC.[8][Level of evidence A1]
Sources: 8 · Level of evidence A1
Conclusions about the efficacy of surgery for patients with local and locoregional NSCLC are limited by the small number of participants studied to date and the potential methodological weaknesses of the trials.
Adjuvant therapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Many patients who have surgery subsequently develop regional or distant metastases.[9] Such patients are candidates for entry into clinical trials evaluating postoperative treatment with chemotherapy or radiation therapy following surgery. At present, neither chemotherapy nor radiation therapy has been found to improve survival in patients with stage I NSCLC that has been completely resected.
Sources: 9
Adjuvant chemotherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Based on a meta-analysis, postoperative chemotherapy is not recommended outside of a clinical trial for patients with completely resected stage I NSCLC.[10] However, there may be some benefit of adjuvant chemotherapy in patients with stage IB tumors that are larger than 4 cm.
Sources: 10
Evidence (adjuvant chemotherapy for patients with stage IB NSCLC):
The Cancer and Leukemia Group B study (CALGB-9633 [NCT00002852]) addressed the results of adjuvant carboplatin and paclitaxel versus observation for OS in 344 patients with resected stage IB (i.e., pathological T2, N0) NSCLC. Within 4 to 8 weeks of resection, patients were randomly assigned to postoperative chemotherapy or observation.[11]
Sources: CALGB-9633 · 11
The Cancer and Leukemia Group B study (CALGB-9633 [NCT00002852]) addressed the results of adjuvant carboplatin and paclitaxel versus observation for OS in 344 patients with resected stage IB (i.e., pathological T2, N0) NSCLC. Within 4 to 8 weeks of resection, patients were randomly assigned to postoperative chemotherapy or observation.[11]
Survival was not significantly different (HR, 0.83; 90% CI, 0.64–1.08; P = .12) at a median follow-up of 74 months.
Grades 3 to 4 neutropenia were the predominant toxicity; there were no treatment-related deaths.
A post-hoc exploratory analysis demonstrated a significant survival difference in favor of postoperative chemotherapy for patients who had tumors 4 cm or larger in diameter (HR, 0.69; 90% CI, 0.48–0.99; P = .043).
Given the magnitude of observed survival differences, CALGB-9633 may have been underpowered to detect small but clinically meaningful improvements in survival. In addition, the use of a carboplatin versus a cisplatin combination might have affected the results. At present, there is no reliable evidence that postoperative chemotherapy improves survival of patients with stage IB NSCLC.[11][Level of evidence A1]
Sources: 11 · Level of evidence A1
Adjuvant targeted therapy (for patients with stage IB NSCLC and EGFR variants)
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Adjuvant targeted therapy with osimertinib for patients with resected stage IB to IIIA NSCLC and an EGFR pathogenic variant was studied in a phase III clinical trial and showed improved OS.
Evidence (adjuvant targeted therapy with osimertinib for patients with stage IB NSCLC and EGFR variants):
The phase III, double-blind, placebo-controlled ADAURA (NCT02511106) trial included 682 patients with surgically resected stage IB to stage IIIA NSCLC and EGFR pathogenic variants (centrally determined, deletion in exon 19 or L858R variant). Patients were randomly assigned to receive either 80 mg of osimertinib by mouth daily (n = 399) or a placebo (n = 342) for 3 years. Standard postoperative adjuvant chemotherapy was allowed but not mandatory; decisions regarding adjuvant chemotherapy were made by the physician and patient before trial enrollment.[12][Level of evidence A1]
Sources: ADAURA · 12 · Level of evidence A1
The phase III, double-blind, placebo-controlled ADAURA (NCT02511106) trial included 682 patients with surgically resected stage IB to stage IIIA NSCLC and EGFR pathogenic variants (centrally determined, deletion in exon 19 or L858R variant). Patients were randomly assigned to receive either 80 mg of osimertinib by mouth daily (n = 399) or a placebo (n = 342) for 3 years. Standard postoperative adjuvant chemotherapy was allowed but not mandatory; decisions regarding adjuvant chemotherapy were made by the physician and patient before trial enrollment.[12][Level of evidence A1]
In the overall population, the 5-year OS rate was 88% in the osimertinib group and 78% in the placebo group (overall HRdeath, 0.49; 95.03% CI, 0.34–0.70; P < .001).
Among patients with stage II to IIIA disease, the 5-year OS rate was 85% in the osimertinib group and 73% in the placebo group (overall HRdeath, 0.49; 95.03% CI, 0.33–0.73; P < .001).
The adverse event profile is consistent with other studies that used osimertinib except for pneumonia related to COVID-19, which was reported later.
The U.S. Food and Drug Administration (FDA) approved osimertinib as adjuvant therapy for patients with stage IB to IIIA NSCLC with EGFR exon 19 deletions or EGFR L858R variants.
Adjuvant targeted therapy (for patients with stage IB tumors and ALK variants)
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Evidence (adjuvant targeted therapy for patients with stage IB tumors with ALK variants):
The global, phase III, open-label ALINA trial (NCT03456076) included 257 patients with completely resected stage IB (tumors ≥4 cm), II, or IIIA (American Joint Committee on Cancer 7th edition staging criteria) NSCLC and an ALK variant. Patients were randomly assigned in a 1:1 ratio to receive either oral alectinib (600 mg twice daily) for 24 months or intravenous platinum-based chemotherapy in four 21-day cycles. The primary end point was DFS, tested hierarchically among patients with stage II or IIIA disease and then in the intention-to-treat (ITT) population. Secondary end points included central nervous system (CNS) DFS, OS, and safety.[13]
The global, phase III, open-label ALINA trial (NCT03456076) included 257 patients with completely resected stage IB (tumors ≥4 cm), II, or IIIA (American Joint Committee on Cancer 7th edition staging criteria) NSCLC and an ALK variant. Patients were randomly assigned in a 1:1 ratio to receive either oral alectinib (600 mg twice daily) for 24 months or intravenous platinum-based chemotherapy in four 21-day cycles. The primary end point was DFS, tested hierarchically among patients with stage II or IIIA disease and then in the intention-to-treat (ITT) population. Secondary end points included central nervous system (CNS) DFS, OS, and safety.[13]
The median duration of follow-up for survival was 27.8 months (27.8 months in the alectinib group and 28.4 months in the chemotherapy group).
The 2-year DFS rate was 93.8% in the alectinib group and 63.0% in the chemotherapy group (stage II/IIIA) (HRdisease recurrence or death, 0.24; 95% CI, 0.13–0.45; P < .001).[13][Level of evidence B1]
Sources: 13 · Level of evidence B1
The ITT population included patients with stage IB, II, or IIIA disease who had been randomly assigned. The DFS rate in the ITT population was 93.6% for patients who received alectinib and 63.7% for patients who received chemotherapy (HR, 0.24; 95% CI, 0.13–0.43; P < .001).
The HRCNS disease recurrence or death was 0.22 (95% CI, 0.08–0.58) in favor of alectinib.
OS data are immature.
The FDA approved alectinib for adjuvant treatment following tumor resection in patients with NSCLC and an ALK variant.
Adjuvant immunotherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Evidence (adjuvant immunotherapy with pembrolizumab for patients with stage IB tumors >4 cm):
The phase III, multicenter, open-label PEARLS/KEYNOTE-091 trial (NCT02504372) randomly assigned 1,177 patients with completely resected stage IB (tumor >4 cm) to stage IIIA NSCLC to receive pembrolizumab (200 mg every 3 weeks) or placebo for up to 18 cycles, or until disease progression or unacceptable toxicity. Patients started study treatment after resection or, if indicated, after adjuvant chemotherapy (maximum of four cycles). The dual primary end points were DFS in the overall study population and DFS in patients with a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) of 50% or greater, as determined using the PD-L1 IHC 22C3 pharmDx assay. These end points were reported in a prespecified interim analysis after a median follow-up of 35.6 months (interquartile range, 27.1–45.5).[14][Level of evidence B1]
Sources: PEARLS/KEYNOTE-091 · 14 · Level of evidence B1
The phase III, multicenter, open-label PEARLS/KEYNOTE-091 trial (NCT02504372) randomly assigned 1,177 patients with completely resected stage IB (tumor >4 cm) to stage IIIA NSCLC to receive pembrolizumab (200 mg every 3 weeks) or placebo for up to 18 cycles, or until disease progression or unacceptable toxicity. Patients started study treatment after resection or, if indicated, after adjuvant chemotherapy (maximum of four cycles). The dual primary end points were DFS in the overall study population and DFS in patients with a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) of 50% or greater, as determined using the PD-L1 IHC 22C3 pharmDx assay. These end points were reported in a prespecified interim analysis after a median follow-up of 35.6 months (interquartile range, 27.1–45.5).[14][Level of evidence B1]
In the overall study population, the median DFS was 53.6 months (95% CI, 39.2–not reached [NR]) in the pembrolizumab group and 42.0 months (95% CI, 31.3–NR) in the placebo group (HR, 0.76; 95% CI, 0.63–0.91; P = .0014).
In the PD-L1 TPS ≥50% population, the median DFS was not reached with either pembrolizumab (95% CI, 44.3–NR) or placebo (95% CI, 35.8–NR) (HR, 0.82; 95% CI, 0.57–1.18; P = .14).
OS data were immature at the time of the prespecified interim analysis.
No new safety signals were identified in this study.
The FDA approved pembrolizumab as a single agent for adjuvant treatment following resection and platinum-based chemotherapy for patients with stage IB (T2a ≥4 cm), II, or IIIA NSCLC. Of note, the FDA label specifies that pembrolizumab can be used as adjuvant therapy after platinum-based chemotherapy. However, chemotherapy was not required in the overall study patient population evaluated in KEYNOTE-091.
Adjuvant external radiation therapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
The value of postoperative (adjuvant) radiation therapy (PORT) has been evaluated and has not been found to improve the outcome of patients with completely resected stage I NSCLC.[15]
Sources: 15
Adjuvant brachytherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
The value of intraoperative (adjuvant) brachytherapy applied to the suture line has been evaluated in patients undergoing sublobar resections for stage I NSCLC to improve local control; it has not been found to improve outcomes.
Evidence (adjuvant brachytherapy):
A phase III trial that randomly assigned 222 patients to undergo sublobar resection with or without suture line brachytherapy reported the following:[16]
Sources: 16
A phase III trial that randomly assigned 222 patients to undergo sublobar resection with or without suture line brachytherapy reported the following:[16]
No difference in the primary end point of local recurrence (5-year estimate, 14.0% vs. 16.7%; P = .59).
No difference in OS rates (5-year estimate, 61.4% vs. 55.6%; P = .38).[16][Level of evidence B1] vs. [Level of evidence A1]
Sources: 16 · Level of evidence B1 · Level of evidence A1
Radiation therapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
A substantial number of patients are ineligible for standard surgical resection because of comorbid conditions that are associated with unacceptably high perioperative risk. Patients with potentially resectable tumors with medical contraindications to surgery or those with inoperable stage I disease and with sufficient pulmonary reserve may be candidates for radiation therapy with curative intent.[17-19] Nonrandomized observational studies comparing treatment outcomes associated with resection, radiation therapy, and observation have demonstrated shorter survival times and higher mortality for patients who undergo observation only.[17,20]
Conventional radiation therapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Historically, conventional primary radiation therapy consisted of approximately 60 Gy to 70 Gy delivered with megavoltage equipment to the midplane of the known tumor volume using conventional fractionation (1.8–2.0 Gy per day).
Improvements in radiation techniques include planning techniques to account for tumor motion, more conformal planning techniques (e.g., 3-D conformal radiation therapy and intensity-modulated radiation therapy), and image guidance during treatment. Modern approaches to delivery of external-beam radiation therapy (EBRT) include hypofractionated radiation therapy and stereotactic body radiation therapy (SBRT). However, there are limited reliable data from comparative trials to determine which approaches yield superior outcomes.[18,19]
Evidence (conventional radiation therapy):
In the largest retrospective conventional radiation therapy series, patients with inoperable disease were treated with definitive radiation therapy.[21-23]
In the largest retrospective conventional radiation therapy series, patients with inoperable disease were treated with definitive radiation therapy.[21-23]
Patients achieved 5-year survival rates of 10% to 30%.[21-23]
Several series demonstrated that patients with T1, N0 tumors had better outcomes, and 5-year survival rates of 30% to 60% were found in this subgroup.[21,22,24]
However, local-only failure occurs in as many as 50% of patients treated with conventional radiation therapy to doses in the range of 60 Gy to 65 Gy.[25,26]
A single report of patients older than 70 years who had resectable lesions smaller than 4 cm but who had medically inoperable disease or who refused surgery reported the following:[24]
Sources: 24
A single report of patients older than 70 years who had resectable lesions smaller than 4 cm but who had medically inoperable disease or who refused surgery reported the following:[24]
Survival at 5 years after radiation therapy with curative intent was comparable with a historical control group of patients of similar age who were resected with curative intent.
A small case series using matched controls reported the following:[4]
Sources: 4
A small case series using matched controls reported the following:[4]
The addition of endobronchial brachytherapy improved local disease control compared with EBRT.[4][Level of evidence C2]
Sources: 4 · Level of evidence C2
Hypofractionated radiation therapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Hypofractionated radiation therapy involves the delivery of a slightly higher dose of radiation therapy per day (e.g., 2.4–4.0 Gy) over a shorter period of time compared with conventionally fractionated radiation therapy. Multiple prospective phase I/II trials have demonstrated that hypofractionated radiation therapy to a dose of 60 Gy to 70 Gy delivered over 3 to 4 weeks with 2.4 Gy to 4.0 Gy per day resulted in a low incidence of moderate to severe toxicity, 2-year OS rates of 50% to 60%, and 2-year tumor local control of 80% to 90%.[27-29][Level of evidence C1]
Sources: 27 · 29 · Level of evidence C1
Stereotactic body radiation therapy (SBRT)
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
SBRT involves the delivery of highly conformal, high-dose radiation therapy over an extremely hypofractionated course (e.g., one to five treatments) delivered over 1 to 2 weeks. Commonly used regimens include 18 Gy × 3, 12 Gy to 12.5 Gy × 4, and 10 Gy to 12 Gy × 5, and deliver a substantially higher biologically effective dose compared with historic conventional radiation therapy regimens.
Multiple prospective phase I/II trials and institutional series have demonstrated that SBRT results in a low incidence of pulmonary toxicity (<10% risk of symptomatic radiation pneumonitis), 2-year OS rates of 50% to 60%, and 2-year tumor control of 90% to 95%.[30-36][Level of evidence C1]
Sources: 30 · 36 · Level of evidence C1
Evidence (SBRT):
Early phase I/II trials from Indiana University identified the maximum tolerated dose of three-fraction SBRT at 18 Gy × 3 for T1 tumors.
Early phase I/II trials from Indiana University identified the maximum tolerated dose of three-fraction SBRT at 18 Gy × 3 for T1 tumors.
This regimen resulted in a 2-year OS rate of 55% and 2-year local tumor control of 95%.
An unacceptably high incidence (8.6%) of grade 5 toxicity was observed in patients with central tumors (defined as within 2 cm of the tracheobronchial tree from the trachea to the level of the lobar bronchi).[31]
Sources: 31
A subsequent multicenter trial (RTOG-0236 [NCT00087438]) studied the 18 Gy × 3 regimen in 55 patients with peripheral T1 to T2 tumors only.
Sources: RTOG-0236
A subsequent multicenter trial (RTOG-0236 [NCT00087438]) studied the 18 Gy × 3 regimen in 55 patients with peripheral T1 to T2 tumors only.
This trial demonstrated a 3-year OS rate of 56% and 3-year primary tumor control of 98%.
The incidence of moderate to severe toxicity was low, with grade 3 toxicity in 24% of patients, grade 4 toxicity in 4% of patients, and no grade 5 toxicity, with a 4% incidence of grade 3 radiation pneumonitis.[35]
Sources: 35
In the largest reported series from VU University Medical Center Amsterdam, 676 patients with T1 to T2 tumors were treated with three-, five-, and eight-fraction SBRT using a risk-adapted approach (a tailored fractionation regimen based on tumor proximity to critical organs).
In the largest reported series from VU University Medical Center Amsterdam, 676 patients with T1 to T2 tumors were treated with three-, five-, and eight-fraction SBRT using a risk-adapted approach (a tailored fractionation regimen based on tumor proximity to critical organs).
With a median follow-up of 32.9 months, the median OS was 40.7 months, and 2-year local tumor control was 95%.[36]
Sources: 36
While central location is a contraindication to three-fraction SBRT based on data from the Indiana phase II study, a subsequent systematic review of published reports of 315 patients with 563 central tumors demonstrated a much lower incidence of severe toxicity, including a 1% to 5% risk of grade 5 events with more protracted SBRT regimens (e.g., four to ten fractions).[37]
Sources: 37
A multicenter phase I/II trial (RTOG-0813 [NCT00750269]) is ongoing to identify the maximum tolerated dose for a five-fraction SBRT regimen for central tumors.
Sources: RTOG-0813
A randomized trial of hypofractionated radiation therapy versus SBRT (LUSTRE [NCT01968941]) is ongoing to determine the optimal radiation therapy regimen, but SBRT has been widely adopted for patients with medically inoperable stage I NSCLC.
Sources: NCT01968941
Treatment of Stages IIA and IIB NSCLC
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Treatment Options for Stages IIA and IIB NSCLC
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Treatment options for stages IIA non-small cell lung cancer (NSCLC) and IIB NSCLC include:
Sources: stages IIA non-small cell lung cancer (NSCLC) · IIB NSCLC
Surgery with or without adjuvant and/or neoadjuvant therapy.
Sources: Surgery with or without adjuvant and/or neoadjuvant therapy
Adjuvant chemotherapy.
Sources: Adjuvant chemotherapy
Adjuvant targeted therapy (for patients with EGFR variants).
Sources: Adjuvant targeted therapy
Adjuvant targeted therapy (for patients with ALK variants).
Sources: Adjuvant targeted therapy
Adjuvant immunotherapy.
Sources: Adjuvant immunotherapy
Adjuvant radiation therapy.
Sources: Adjuvant radiation therapy
Neoadjuvant chemotherapy.
Sources: Neoadjuvant chemotherapy
Neoadjuvant immunotherapy with chemotherapy.
Surgery with or without adjuvant and/or neoadjuvant therapy. › Neoadjuvant immunotherapy with chemotherapy.
Nivolumab plus platinum-based chemotherapy.
Surgery with or without adjuvant and/or neoadjuvant therapy.
Perioperative (neoadjuvant and adjuvant) immunotherapy with neoadjuvant chemotherapy.
Sources: Perioperative (neoadjuvant and adjuvant) immunotherapy with neoadjuvant chemotherapy
Surgery with or without adjuvant and/or neoadjuvant therapy. › Perioperative (neoadjuvant and adjuvant) immunotherapy with neoadjuvant chemotherapy.
Perioperative pembrolizumab plus platinum-based chemotherapy.
Sources: Perioperative pembrolizumab plus platinum-based chemotherapy
Perioperative durvalumab plus platinum-based chemotherapy.
Sources: Perioperative durvalumab plus platinum-based chemotherapy
Perioperative nivolumab plus platinum-based chemotherapy.
Sources: Perioperative nivolumab plus platinum-based chemotherapy
Perioperative toripalimab plus platinum-based chemotherapy.
Sources: Perioperative toripalimab plus platinum-based chemotherapy
Radiation therapy (for patients who cannot have surgery).
Sources: Radiation therapy
Clinical trials of radiation therapy after curative surgery.
Adjuvant radiation therapy has not been shown to improve outcomes in patients with stage II NSCLC.
Surgery with or without adjuvant or neoadjuvant therapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Surgery alone
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Surgery is the treatment of choice for patients with stage II NSCLC. A lobectomy, pneumonectomy, segmental resection, wedge resection, or sleeve resection may be performed as appropriate. Careful preoperative assessment of the patient’s overall medical condition, especially the patient’s pulmonary reserve, is critical in considering the benefits of surgery. In addition to the immediate and age-related postoperative mortality rate, a 5% to 8% mortality rate with pneumonectomy or a 3% to 5% mortality rate with lobectomy can be expected.
Evidence (surgery):
The Cochrane Collaboration reviewed 11 randomized trials with a total of 1,910 patients who underwent surgical interventions for early-stage (I–IIIA) lung cancer.[1] A pooled analysis of three trials reported the following:
Sources: 1
The Cochrane Collaboration reviewed 11 randomized trials with a total of 1,910 patients who underwent surgical interventions for early-stage (I–IIIA) lung cancer.[1] A pooled analysis of three trials reported the following:
Four-year survival was superior in patients with resectable stage I, II, or IIIA NSCLC who underwent resection and complete ipsilateral mediastinal lymph node dissection (CMLND), compared with those who underwent resection and lymph node sampling; the hazard ratio (HR) was estimated to be 0.78 (95% confidence interval [CI], 0.65–0.93; P = .005).[1][Level of evidence A1]
Sources: 1 · Level of evidence A1
There was a significant reduction in any cancer recurrence (local or distant) in the CMLND group (relative risk [RR], 0.79; 95% CI, 0.66–0.95; P = .01) that appeared mainly as the result of a reduction in the number of distant recurrences (RR, 0.78; 95% CI, 0.61–1.00; P = .05).
There was no difference in operative mortality.
Air leak lasting more than 5 days was significantly more common in patients assigned to CMLND (RR, 2.94; 95% CI, 1.01–8.54; P = .05).
CMLND versus lymph node sampling was evaluated in a large randomized phase III trial (ACOSOG-Z0030 [NCT00003831]).[2]
Sources: ACOSOG-Z0030 · 2
CMLND versus lymph node sampling was evaluated in a large randomized phase III trial (ACOSOG-Z0030 [NCT00003831]).[2]
Preliminary analyses of operative morbidity and mortality showed comparable rates from the procedures.[2]
Sources: 2
There was no difference in overall survival (OS), disease-free survival (DFS), local recurrence, and regional recurrence.[3][Level of evidence A1]
Sources: 3 · Level of evidence A1
Evidence suggests that lung cancer resection combined with CMLND is not associated with improvement in survival compared with lung cancer resection combined with systematic sampling of mediastinal lymph nodes in patients with stage I, II, or IIIA NSCLC.[3][Level of evidence A1]
Sources: 3 · Level of evidence A1
Conclusions about the efficacy of surgery for patients with local and locoregional NSCLC are limited by the small number of participants studied and potential methodological weaknesses of the trials.
Adjuvant chemotherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
The preponderance of evidence indicates that postoperative cisplatin combination chemotherapy provides a significant survival advantage to patients with resected stage II NSCLC. Preoperative chemotherapy may also provide survival benefit. The optimal sequence of surgery and chemotherapy and the benefits and risks of postoperative radiation therapy in patients with resectable NSCLC remain to be determined.
After surgery, many patients develop regional or distant metastases.[4] Several randomized controlled trials and meta-analyses have evaluated the use of postoperative chemotherapy in patients with stage I, II, and IIIA NSCLC.[5-11]
Evidence (adjuvant chemotherapy):
Data on individual patient outcomes were collected and pooled into a meta-analysis from the five largest trials (4,584 patients) of cisplatin-based chemotherapy in patients with completely resected NSCLC that were conducted after 1995.[7]
Sources: 7
Data on individual patient outcomes were collected and pooled into a meta-analysis from the five largest trials (4,584 patients) of cisplatin-based chemotherapy in patients with completely resected NSCLC that were conducted after 1995.[7]
With a median follow-up time of 5.2 years, the overall HRdeath was 0.89 (95% CI, 0.82–0.96; P = .005), corresponding to a 5-year absolute benefit of 5.4% from chemotherapy.
The benefit varied with stage (test for trend, P = .04; HR for stage IA, 1.40; 95% CI, 0.95–2.06; HR for stage IB, 0.93; 95% CI, 0.78–1.10; HR for stage II, 0.83; 95% CI, 0.73–0.95; and HR for stage III, 0.83; 95% CI, 0.72–0.94).
The effect of chemotherapy did not vary significantly (test for interaction, P = .11) with the associated drugs, including vinorelbine (HR, 0.80; 95% CI, 0.70–0.91), etoposide or vinca alkaloid (HR, 0.92; 95% CI, 0.80–1.07), or other drugs (HR, 0.97; 95% CI, 0.84–1.13).
The greater effect on survival observed with the doublet of cisplatin plus vinorelbine compared with other regimens should be interpreted cautiously as the total dose of cisplatin received was significantly higher in patients treated with vinorelbine.
The meta-analysis [7] and the individual studies [5,12] support the administration of postoperative cisplatin-based chemotherapy in combination with vinorelbine.
The meta-analysis [7] and the individual studies [5,12] support the administration of postoperative cisplatin-based chemotherapy in combination with vinorelbine.
Superior OS for the trial population and patients with stage II disease was reported for the Lung Adjuvant Cisplatin Evaluation (LACE) pooled analysis (pooled HR, 0.83; 95% CI, 0.73–0.95); the Adjuvant Navelbine International Trialist Association (ANITA) trial (HR, 0.71; 95% CI, 0.49–1.03); and the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial (HR, 0.59; 95% CI, 0.42–0.85).
Chemotherapy effect was higher in patients with better performance status.
There was no interaction between chemotherapy effect and any of the following:
The meta-analysis [7] and the individual studies [5,12] support the administration of postoperative cisplatin-based chemotherapy in combination with vinorelbine. › There was no interaction between chemotherapy effect and any of the following:
Sex.
Age.
Histology.
Type of surgery.
Planned radiation therapy.
Planned total dose of cisplatin.
In a retrospective analysis of a phase III trial of postoperative cisplatin and vinorelbine, patients older than 65 years were found to benefit from treatment.[13]
Sources: 13
In a retrospective analysis of a phase III trial of postoperative cisplatin and vinorelbine, patients older than 65 years were found to benefit from treatment.[13]
Chemotherapy significantly prolonged OS for patients older than 65 years (HR, 0.61; 95% CI, 0.38–0.98; P = .04).
There were no significant differences in toxic effects, hospitalization, or treatment-related death by age group, although patients older than 65 years received less treatment.[13]
Sources: 13
Several other randomized controlled trials and meta-analyses have evaluated the use of postoperative chemotherapy in patients with stages I, II, and IIIA NSCLC.[5-11]
Based on these data, patients with completely resected stage II lung cancer may benefit from postoperative cisplatin-based chemotherapy.[13][Level of evidence A1]
Sources: 13 · Level of evidence A1
Adjuvant targeted therapy (for patients with EGFR variants)
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Adjuvant targeted therapy with osimertinib for patients with resected stage IB to IIIA NSCLC and an EGFR pathogenic variant was studied in a phase III clinical trial and showed improved OS.
Evidence (adjuvant targeted therapy with osimertinib for patients with stages IIA and IIB NSCLC and an EGFR variant):
The phase III, double-blind, placebo-controlled ADAURA (NCT02511106) trial included 682 patients with surgically resected stage IB to stage IIIA NSCLC and EGFR pathogenic variants (centrally determined, deletion in exon 19 or L858R variant). Patients were randomly assigned to receive 80 mg of osimertinib by mouth daily (n = 399) or a placebo (n = 342) for 3 years. Standard postoperative adjuvant chemotherapy was allowed but not mandatory; decisions regarding adjuvant chemotherapy were made by the physician and patient before trial enrollment.[14][Level of evidence A1]
Sources: ADAURA · 14 · Level of evidence A1
The phase III, double-blind, placebo-controlled ADAURA (NCT02511106) trial included 682 patients with surgically resected stage IB to stage IIIA NSCLC and EGFR pathogenic variants (centrally determined, deletion in exon 19 or L858R variant). Patients were randomly assigned to receive 80 mg of osimertinib by mouth daily (n = 399) or a placebo (n = 342) for 3 years. Standard postoperative adjuvant chemotherapy was allowed but not mandatory; decisions regarding adjuvant chemotherapy were made by the physician and patient before trial enrollment.[14][Level of evidence A1]
In the overall population, the 5-year OS rate was 88% in the osimertinib group and 78% in the placebo group (overall HRdeath, 0.49; 95.03% CI, 0.34–0.70; P < .001).
Among patients with stage II to IIIA disease, the 5-year OS rate was 85% in the osimertinib group and 73% in the placebo group (overall HRdeath, 0.49; 95.03% CI, 0.33–0.73; P < .001).
The adverse event profile is consistent with other studies that used osimertinib except for pneumonia related to COVID-19, which was reported later.
The U.S. Food and Drug Administration (FDA) approved osimertinib as adjuvant therapy for patients with stage IB to IIIA NSCLC with EGFR exon 19 deletions or EGFR L858R variants.
Adjuvant targeted therapy (for patients with ALK variants)
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Evidence (adjuvant targeted therapy (for patients with ALK variants).
The global, phase III, open-label ALINA trial (NCT03456076) included 257 patients with completely resected stage IB (tumors ≥4 cm), II, or IIIA (American Joint Committee on Cancer 7th edition staging criteria) NSCLC and an ALK variant. Patients were randomly assigned in a 1:1 ratio to receive either oral alectinib (600 mg twice daily) for 24 months or intravenous platinum-based chemotherapy in four 21-day cycles. The primary end point was DFS, tested hierarchically among patients with stage II or IIIA disease and then in the intention-to-treat (ITT) population. Secondary end points included central nervous system (CNS) DFS, OS, and safety.[15]
The global, phase III, open-label ALINA trial (NCT03456076) included 257 patients with completely resected stage IB (tumors ≥4 cm), II, or IIIA (American Joint Committee on Cancer 7th edition staging criteria) NSCLC and an ALK variant. Patients were randomly assigned in a 1:1 ratio to receive either oral alectinib (600 mg twice daily) for 24 months or intravenous platinum-based chemotherapy in four 21-day cycles. The primary end point was DFS, tested hierarchically among patients with stage II or IIIA disease and then in the intention-to-treat (ITT) population. Secondary end points included central nervous system (CNS) DFS, OS, and safety.[15]
The median duration of follow-up for survival was 27.8 months (27.8 months in the alectinib group and 28.4 months in the chemotherapy group).
The 2-year DFS rate was 93.8% in the alectinib group and 63.0% in the chemotherapy group (stage II/IIIA) (HRdisease recurrence or death, 0.24; 95% CI, 0.13–0.45; P < .001).[15][Level of evidence B1]
Sources: 15 · Level of evidence B1
The ITT population included patients with stage IB, II, or IIIA disease who had been randomly assigned. The DFS rate in the ITT population was 93.6% for patients who received alectinib and 63.7% for patients who received chemotherapy (HR, 0.24; 95% CI, 0.13–0.43; P < .001).
The HRCNS disease recurrence or death was 0.22 (95% CI, 0.08–0.58) in favor of alectinib.
OS data are immature.
The FDA approved alectinib for adjuvant treatment following tumor resection in patients with NSCLC and an ALK variant.
Adjuvant immunotherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Adjuvant immunotherapy for patients with resected stage IB to IIIA NSCLC has been found to significantly increase DFS.[16,17]
Evidence (adjuvant immunotherapy with pembrolizumab for patients with stage IIA and IIB tumors >4 cm):
The phase III, multicenter, open-label PEARLS/KEYNOTE-091 trial (NCT02504372) randomly assigned 1,177 patients with completely resected stage IB (tumor >4 cm) to stage IIIA NSCLC to receive pembrolizumab (200 mg every 3 weeks) or placebo for up to 18 cycles, or until disease progression or unacceptable toxicity. Patients started study treatment after resection or, if indicated, after adjuvant chemotherapy (maximum of four cycles). The dual primary end points were DFS in the overall study population and DFS in patients with a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) of 50% or greater, as determined using the PD-L1 IHC 22C3 pharmDx assay. These end points were reported in a prespecified interim analysis after a median follow-up of 35.6 months (interquartile range [IQR], 27.1–45.5).[16][Level of evidence B1]
Sources: PEARLS/KEYNOTE-091 · 16 · Level of evidence B1
The phase III, multicenter, open-label PEARLS/KEYNOTE-091 trial (NCT02504372) randomly assigned 1,177 patients with completely resected stage IB (tumor >4 cm) to stage IIIA NSCLC to receive pembrolizumab (200 mg every 3 weeks) or placebo for up to 18 cycles, or until disease progression or unacceptable toxicity. Patients started study treatment after resection or, if indicated, after adjuvant chemotherapy (maximum of four cycles). The dual primary end points were DFS in the overall study population and DFS in patients with a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) of 50% or greater, as determined using the PD-L1 IHC 22C3 pharmDx assay. These end points were reported in a prespecified interim analysis after a median follow-up of 35.6 months (interquartile range [IQR], 27.1–45.5).[16][Level of evidence B1]
In the overall study population, the median DFS was 53.6 months (95% CI, 39.2–not reached [NR]) in the pembrolizumab group and 42.0 months (95% CI, 31.3–NR) in the placebo group (HR, 0.76; 95% CI, 0.63–0.91; P = .0014).
In the PD-L1 TPS ≥50% population, the median DFS was not reached with either pembrolizumab (95% CI, 44.3–NR) or placebo (95% CI, 35.8–NR) (HR, 0.82; 95% CI, 0.57–1.18; P = .14).
OS data were immature at the time of the prespecified interim analysis.
No new safety signals were identified in this study.
The FDA approved pembrolizumab as a single agent for adjuvant treatment following resection and platinum-based chemotherapy for patients with stage IB (T2a ≥4 cm), II, or IIIA NSCLC. Of note, the FDA label specifies that pembrolizumab can be used as adjuvant therapy after platinum-based chemotherapy. However, chemotherapy was not required in the overall study patient population evaluated in KEYNOTE-091.
Evidence (adjuvant immunotherapy with atezolizumab for patients with stages IIA and IIB NSCLC):
IMpower010 (NCT02486718) was a phase III, multicenter, open-label trial that randomly assigned 1,005 patients with surgically resected stage IB (tumor >4 cm) to stage IIIA NSCLC. Patients received atezolizumab (1,200 mg every 21 days intravenously) or best supportive care for 16 cycles or 1 year after standard adjuvant platinum-based chemotherapy. Patients were enrolled after resection if they were eligible for cisplatin-based chemotherapy and were randomized after completion of chemotherapy if they remained eligible and did not experience disease progression. The primary end point was investigator-assessed DFS.[17]
Sources: IMpower010 · 17
IMpower010 (NCT02486718) was a phase III, multicenter, open-label trial that randomly assigned 1,005 patients with surgically resected stage IB (tumor >4 cm) to stage IIIA NSCLC. Patients received atezolizumab (1,200 mg every 21 days intravenously) or best supportive care for 16 cycles or 1 year after standard adjuvant platinum-based chemotherapy. Patients were enrolled after resection if they were eligible for cisplatin-based chemotherapy and were randomized after completion of chemotherapy if they remained eligible and did not experience disease progression. The primary end point was investigator-assessed DFS.[17]
The primary end point was tested hierarchically, first in the stage II to IIIA population subgroup whose tumors expressed PD-L1 on at least 1% of tumor cells (using the SP263 antibody), then in all patients in the stage II to IIIA population, and finally in the ITT population (stage IB to IIIA). Of the 882 patients who were randomly assigned and had stage II to IIIA disease, 476 had tumors expressing PD-L1 on at least 1% of tumor cells per SP263.[17][Level of evidence B1]
Sources: 17 · Level of evidence B1
After a median follow-up of 32.2 months, atezolizumab treatment improved DFS compared with best supportive care in patients in the stage II to IIIA population whose tumors expressed PD-L1 on at least 1% of tumor cells (HR, 0.66; 95% CI, 0.50–0.88; P = .0039). At 24 months, the DFS rate was 74.6% for the atezolizumab group and 61.0% for the best supportive care group.
Atezolizumab also improved DFS in all patients in the stage II to IIIA population (HR, 0.79; 95% CI, 0.64–0.96; P = .020). At 24 months, the DFS rate was 70.2% for the atezolizumab group and 61.6% for the best supportive care group.
In the ITT population, which included patients with stage IB to IIIA disease, HRDFS was 0.81 (95% CI, 0.67–0.99; P = .040). However, the boundary for statistical significance for DFS was not crossed.
OS data are immature.
No new safety signals were noted.
The FDA approved atezolizumab for adjuvant treatment of patients with stage II to IIIA NSCLC whose tumors express PD-L1 on at least 1% of tumor cells.
Adjuvant radiation therapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
The value of postoperative (adjuvant) radiation therapy (PORT) has been evaluated.[18]
Sources: 18
Evidence (adjuvant radiation therapy):
A meta-analysis, based on the results of ten randomized controlled trials and 2,232 individuals, reported the following:[18]
Sources: 18
A meta-analysis, based on the results of ten randomized controlled trials and 2,232 individuals, reported the following:[18]
An 18% relative increase in the risk of death for patients who received PORT compared with surgery alone (HR, 1.18; P = .002). This is equivalent to an absolute detriment of 6% at 2 years (95% CI, 2%–9%), reducing OS from 58% to 52%. Exploratory subgroup analyses suggested that this detrimental effect was most pronounced for patients with stage I/II, N0 to N1 disease, whereas for patients with stage III, N2 disease there was no clear evidence of an adverse effect.
Results for local (HR, 1.13; P = .02), distant (HR, 1.14; P = .02), and overall (HR, 1.10; P = .06) recurrence-free survival similarly showed a detriment of PORT.[18][Level of evidence A1]
Sources: 18 · Level of evidence A1
Further analysis is needed to determine whether these outcomes can potentially be modified with technical improvements, better definitions of target volumes, and limitation of cardiac volume in the radiation portals.
Neoadjuvant chemotherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
The role of chemotherapy before surgery was tested in clinical trials. The proposed benefits of preoperative chemotherapy include:
A reduction in tumor size that may facilitate surgical resection.
Early eradication of micrometastases.
Better tolerability.
Preoperative chemotherapy may, however, delay potentially curative surgery.
Evidence (neoadjuvant chemotherapy):
The Cochrane Collaboration reported a systematic review and meta-analysis of seven randomized controlled trials that included 988 patients and evaluated the addition of preoperative chemotherapy to surgery versus surgery alone. These trials evaluated patients with stages I, II, and IIIA NSCLC.[19]
Sources: 19
The Cochrane Collaboration reported a systematic review and meta-analysis of seven randomized controlled trials that included 988 patients and evaluated the addition of preoperative chemotherapy to surgery versus surgery alone. These trials evaluated patients with stages I, II, and IIIA NSCLC.[19]
Preoperative chemotherapy provided an absolute benefit in survival of 6% across all stages of disease, from 14% to 20% at 5 years (HR, 0.82; 95% CI, 0.69–0.97; P = .022).[19][Level of evidence A1]
Sources: 19 · Level of evidence A1
This analysis was unable to address questions such as whether particular types of patients may benefit more or less from preoperative chemotherapy.
In the largest trial reported to date, 519 patients were randomly assigned to receive either surgery alone or three cycles of platinum-based chemotherapy followed by surgery. Most patients (61%) had clinical stage I disease; 31% had stage II disease; and 7% had stage III disease.[20]
Sources: 20
In the largest trial reported to date, 519 patients were randomly assigned to receive either surgery alone or three cycles of platinum-based chemotherapy followed by surgery. Most patients (61%) had clinical stage I disease; 31% had stage II disease; and 7% had stage III disease.[20]
No survival advantage was seen.[20]
Sources: 20
Postoperative complications were similar between groups, and no impairment of quality of life was observed.
There was no evidence of a benefit in terms of OS (HR, 1.02; 95% CI, 0.80–1.31; P = .86).
Updating the systematic review by addition of the present result suggests a 12% relative survival benefit with the addition of neoadjuvant (preoperative) chemotherapy (1,507 patients; HR, 0.88; 95% CI, 0.76–1.01; P = .07), equivalent to an absolute improvement in survival of 5% at 5 years.
Neoadjuvant immunotherapy with chemotherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Nivolumab plus platinum-based chemotherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Evidence (nivolumab plus platinum-based chemotherapy):
Checkmate 77T (NCT04025879) was a phase III double-blind trial that enrolled 735 patients with resectable stage IIA (>4 cm) to IIIB (N2 node stage, single- or multistation) NSCLC. Patients had no EGFR variants or known ALK translocations. Patients were randomly assigned to receive either neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo every 3 weeks for four cycles, followed by surgery and adjuvant nivolumab or placebo every 4 weeks for 1 year. The primary end point was event-free survival (EFS) according to blinded independent review. Secondary end points were pathological complete response and major pathological response according to blinded independent review, OS, and safety.[21]
Sources: Checkmate 77T · 21
Checkmate 77T (NCT04025879) was a phase III double-blind trial that enrolled 735 patients with resectable stage IIA (>4 cm) to IIIB (N2 node stage, single- or multistation) NSCLC. Patients had no EGFR variants or known ALK translocations. Patients were randomly assigned to receive either neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo every 3 weeks for four cycles, followed by surgery and adjuvant nivolumab or placebo every 4 weeks for 1 year. The primary end point was event-free survival (EFS) according to blinded independent review. Secondary end points were pathological complete response and major pathological response according to blinded independent review, OS, and safety.[21]
At median follow-up of 25.4 months (range, 15.7–44.2), the 18-month EFS rate was 70.2% in the nivolumab group and 50.0% in the chemotherapy group (HRdisease progression or recurrence, abandoned surgery, or death, 0.58; 97.36% CI, 0.42–0.81; P < .001).[21][Level of evidence B1]
Sources: 21 · Level of evidence B1
The pathological complete response rate was 25.3% in the nivolumab group and 4.7% in the chemotherapy group (odds ratio [OR], 6.64; 95% CI, 3.40–12.97).
The major pathological response rate (≤10% residual viable tumor cells after surgery in the primary tumor and sampled lymph nodes) was 35.4% in the nivolumab group and 12.1% in the chemotherapy group (OR, 4.01; 95% CI, 2.48–6.49).
Grade 3 or 4 treatment-related adverse events occurred in 32.5% of patients in the nivolumab group and 25.2% of patients in the chemotherapy group.
The FDA approved nivolumab with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab after surgery as adjuvant treatment, for adults with resectable (tumors ≥4 cm and/or node positive) NSCLC and no EGFR variants or ALK rearrangements.
Perioperative (neoadjuvant and adjuvant) immunotherapy with chemotherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Several immune checkpoint inhibitors have been approved by the FDA for select patient populations with potentially resectable NSCLC, either in the neoadjuvant setting (nivolumab) or adjuvant setting (atezolizumab, durvalumab, or pembrolizumab). Ongoing phase III trials are evaluating the role of perioperative immune checkpoint inhibitors. These regimens for patients with potentially resectable stages II to III NSCLC include neoadjuvant immune checkpoint inhibitors with chemotherapy followed by surgery and adjuvant immune checkpoint inhibitors. Compared with neoadjuvant chemotherapy alone, early results from studies of perioperative immune checkpoint inhibitor regimens have shown improvements in several key outcomes including EFS, major pathological response, pathological complete response, and OS.
Perioperative pembrolizumab plus platinum-based chemotherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Evidence (neoadjuvant pembrolizumab plus chemotherapy and adjuvant pembrolizumab):
The phase III double-blind KEYNOTE-671 (NCT03425643) trial included 797 patients with untreated stage II, IIIA, or IIIB (≥1 ipsilateral mediastinal node or subcarinal node) NSCLC. Patients were randomly assigned to receive neoadjuvant pembrolizumab (200 mg every 3 weeks) or placebo with cisplatin-based chemotherapy for four cycles, followed by surgery and adjuvant pembrolizumab or placebo for up to 13 cycles, or until disease progression or unacceptable toxicity. The dual primary end points were EFS (defined as the time from randomization to local progression precluding surgery, unresectable tumor, progression or recurrence, or death) and OS. At the second interim analysis, the median follow-up was 36.6 months (range, 27.6–47.8).[22][Level of evidence A1]
Sources: KEYNOTE-671 · 22 · Level of evidence A1
The phase III double-blind KEYNOTE-671 (NCT03425643) trial included 797 patients with untreated stage II, IIIA, or IIIB (≥1 ipsilateral mediastinal node or subcarinal node) NSCLC. Patients were randomly assigned to receive neoadjuvant pembrolizumab (200 mg every 3 weeks) or placebo with cisplatin-based chemotherapy for four cycles, followed by surgery and adjuvant pembrolizumab or placebo for up to 13 cycles, or until disease progression or unacceptable toxicity. The dual primary end points were EFS (defined as the time from randomization to local progression precluding surgery, unresectable tumor, progression or recurrence, or death) and OS. At the second interim analysis, the median follow-up was 36.6 months (range, 27.6–47.8).[22][Level of evidence A1]
The median EFS was 47.2 months (95% CI, 32.9–NR) in the pembrolizumab group and 18.3 months (95% CI, 14.8–22.1) in the placebo group (HR, 0.59; 95% CI, 0.48–0.72).
The 36-month OS rate estimates were 71% (95% CI, 66%–76%) in the pembrolizumab group and 64% (95% CI, 58%–69%) in the placebo group (HR, 0.72; 95% CI, 0.56–0.93; one-sided P = .0052; threshold, one-sided P = .0054).
Secondary end points were reported as follows:
The phase III double-blind KEYNOTE-671 (NCT03425643) trial included 797 patients with untreated stage II, IIIA, or IIIB (≥1 ipsilateral mediastinal node or subcarinal node) NSCLC. Patients were randomly assigned to receive neoadjuvant pembrolizumab (200 mg every 3 weeks) or placebo with cisplatin-based chemotherapy for four cycles, followed by surgery and adjuvant pembrolizumab or placebo for up to 13 cycles, or until disease progression or unacceptable toxicity. The dual primary end points were EFS (defined as the time from randomization to local progression precluding surgery, unresectable tumor, progression or recurrence, or death) and OS. At the second interim analysis, the median follow-up was 36.6 months (range, 27.6–47.8).[22][Level of evidence A1] › Secondary end points were reported as follows:
Major pathological response occurred in 30.2% of patients in the pembrolizumab group and 11.0% of patients in the placebo group (P < .0001).
Pathological complete response occurred in 18.1% of patients in the pembrolizumab group and 4.0% of patients in the placebo group (P < .0001).
The phase III double-blind KEYNOTE-671 (NCT03425643) trial included 797 patients with untreated stage II, IIIA, or IIIB (≥1 ipsilateral mediastinal node or subcarinal node) NSCLC. Patients were randomly assigned to receive neoadjuvant pembrolizumab (200 mg every 3 weeks) or placebo with cisplatin-based chemotherapy for four cycles, followed by surgery and adjuvant pembrolizumab or placebo for up to 13 cycles, or until disease progression or unacceptable toxicity. The dual primary end points were EFS (defined as the time from randomization to local progression precluding surgery, unresectable tumor, progression or recurrence, or death) and OS. At the second interim analysis, the median follow-up was 36.6 months (range, 27.6–47.8).[22][Level of evidence A1]
Grade 3 to 5 treatment-related adverse events occurred in 179 of 396 patients (45%) in the pembrolizumab group and in 151 of 399 patients (38%) in the placebo group. Treatment-related adverse events led to death in four patients (1%) in the pembrolizumab group and three patients (1%) in the placebo group.
Perioperative durvalumab plus platinum-based chemotherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Evidence (durvalumab plus platinum-based chemotherapy):
The phase III AEGEAN trial (NCT03800134) investigated perioperative durvalumab plus neoadjuvant chemotherapy compared with neoadjuvant chemotherapy alone in patients with resectable (stage II to IIIB [N2]) NSCLC. Patients received four cycles of treatment every 3 weeks before surgery, followed by adjuvant durvalumab or placebo intravenously every 4 weeks for 12 cycles. The modified intention-to-treat population (740 patients) included all patients who were randomly assigned, excluding patients with documented EGFR or ALK alterations. The first planned interim analysis occurred with 31.9% data maturity and at a median follow-up of 1 year. The primary end points were EFS and pathological complete response.[23][Level of evidence B1]
Sources: AEGEAN · 23 · Level of evidence B1
The phase III AEGEAN trial (NCT03800134) investigated perioperative durvalumab plus neoadjuvant chemotherapy compared with neoadjuvant chemotherapy alone in patients with resectable (stage II to IIIB [N2]) NSCLC. Patients received four cycles of treatment every 3 weeks before surgery, followed by adjuvant durvalumab or placebo intravenously every 4 weeks for 12 cycles. The modified intention-to-treat population (740 patients) included all patients who were randomly assigned, excluding patients with documented EGFR or ALK alterations. The first planned interim analysis occurred with 31.9% data maturity and at a median follow-up of 1 year. The primary end points were EFS and pathological complete response.[23][Level of evidence B1]
At 12 months, the EFS rate was 73.4% for patients who received durvalumab (95% CI, 67.9%–78.1%), and 64.5% for patients who received chemotherapy alone (95% CI, 58.8%–69.6%).
Pathological complete response was significantly higher with perioperative durvalumab (17.2%), compared with chemotherapy alone (4.3%, P < .001).
The EFS and pathological complete response benefit were observed regardless of stage and PD-L1 expression.
The safety profile was consistent with known profiles of durvalumab and chemotherapy.
Perioperative nivolumab plus platinum-based chemotherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Evidence (neoadjuvant nivolumab plus chemotherapy and adjuvant nivolumab):
Checkmate 77T (NCT04025879) was a phase III double-blind trial that enrolled 735 patients with resectable stage IIA (>4 cm) to IIIB (N2 node stage, single- or multistation) NSCLC. Patients had no EGFR variants or known ALK translocations. Patients were randomly assigned to receive either neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo every 3 weeks for four cycles, followed by surgery and adjuvant nivolumab or placebo every 4 weeks for 1 year. The primary end point was EFS according to blinded independent review. Secondary end points were pathological complete response and major pathological response according to blinded independent review, OS, and safety.[21]
Sources: Checkmate 77T · 21
Checkmate 77T (NCT04025879) was a phase III double-blind trial that enrolled 735 patients with resectable stage IIA (>4 cm) to IIIB (N2 node stage, single- or multistation) NSCLC. Patients had no EGFR variants or known ALK translocations. Patients were randomly assigned to receive either neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo every 3 weeks for four cycles, followed by surgery and adjuvant nivolumab or placebo every 4 weeks for 1 year. The primary end point was EFS according to blinded independent review. Secondary end points were pathological complete response and major pathological response according to blinded independent review, OS, and safety.[21]
At median follow-up of 25.4 months (range, 15.7–44.2), the 18-month EFS rate was 70.2% in the nivolumab group and 50.0% in the chemotherapy group (HRdisease progression or recurrence, abandoned surgery, or death, 0.58; 97.36% CI, 0.42–0.81; P < .001).[21][Level of evidence B1]
Sources: 21 · Level of evidence B1
The pathological complete response rate was 25.3% in the nivolumab group and 4.7% in the chemotherapy group (OR, 6.64; 95% CI, 3.40–12.97).
The major pathological response rate (≤10% residual viable tumor cells after surgery in the primary tumor and sampled lymph nodes) was 35.4% in the nivolumab group and 12.1% in the chemotherapy group (OR, 4.01; 95% CI, 2.48–6.49).
Grade 3 or 4 treatment-related adverse events occurred in 32.5% of patients in the nivolumab group and 25.2% of patients in the chemotherapy group.
Perioperative toripalimab plus platinum-based chemotherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Evidence (toripalimab plus platinum-based chemotherapy):
A phase III randomized trial (Neotorch [NCT04158440]) evaluated the efficacy and safety of toripalimab in combination with neoadjuvant platinum-based chemotherapy followed by maintenance toripalimab versus chemotherapy alone in patients with resectable stage II, IIIA, or IIIB (N2) NSCLC without EGFR or ALK alterations. Patients were stratified by disease stage (II, IIIA, or IIIB), PD-L1 tumor expression status (≥1%, <1%, or not evaluable using the JS311IHC staining assay), planned surgical approach (pneumonectomy or lobectomy), and histological subtype (squamous vs. nonsquamous). A total of 501 patients with stage II to III resectable NSCLC were randomly assigned to receive either (1) toripalimab plus platinum-based chemotherapy for three cycles before surgery and one cycle after surgery followed by single-agent maintenance toripalimab for up to 13 cycles or (2) platinum-based chemotherapy alone for three cycles before surgery and one cycle after surgery. Coprimary end points were EFS (defined as time from randomization to the first documentation of disease progression leading to the inability to operate, postoperative progression, or local or distant recurrence/death from any cause) and major pathological response (≤10% or less viable tumor cells in the tumor bed). Secondary end points included OS, pathological complete response, DFS after surgery, and safety.[24]
A phase III randomized trial (Neotorch [NCT04158440]) evaluated the efficacy and safety of toripalimab in combination with neoadjuvant platinum-based chemotherapy followed by maintenance toripalimab versus chemotherapy alone in patients with resectable stage II, IIIA, or IIIB (N2) NSCLC without EGFR or ALK alterations. Patients were stratified by disease stage (II, IIIA, or IIIB), PD-L1 tumor expression status (≥1%, <1%, or not evaluable using the JS311IHC staining assay), planned surgical approach (pneumonectomy or lobectomy), and histological subtype (squamous vs. nonsquamous). A total of 501 patients with stage II to III resectable NSCLC were randomly assigned to receive either (1) toripalimab plus platinum-based chemotherapy for three cycles before surgery and one cycle after surgery followed by single-agent maintenance toripalimab for up to 13 cycles or (2) platinum-based chemotherapy alone for three cycles before surgery and one cycle after surgery. Coprimary end points were EFS (defined as time from randomization to the first documentation of disease progression leading to the inability to operate, postoperative progression, or local or distant recurrence/death from any cause) and major pathological response (≤10% or less viable tumor cells in the tumor bed). Secondary end points included OS, pathological complete response, DFS after surgery, and safety.[24]
In a prespecified interim analysis of EFS in patients with stage III NSCLC (n = 404) after a median follow-up of 18.3 months (IQR, 12.7–22.5 months), the median EFS was not reached (95% CI, 24.4 months–NR) in the toripalimab group and was 15.1 months (95% CI, 10.6–21.9) in the placebo group (HR, 0.40; 95% CI, 0.28–0.57; P < .001).
The 1- and 2-year EFS rates were 84.4% and 64.7%, respectively, in the toripalimab group and 57.0% and 38.7%, respectively, in the placebo group. A consistent effect on EFS, favoring toripalimab, was observed in all subgroups.
After surgical resection, a major pathological response occurred in 98 patients (48.5%) in the toripalimab group and 17 patients (8.4%) in the placebo group (between group difference, 40.2%; 95% CI, 32.2%–48.1%; P < .001).
The FDA has not approved this drug for patients with lung cancer.
Radiation therapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Patients with potentially operable tumors with medical contraindications to surgery or those with inoperable stage II disease and with sufficient pulmonary reserve are candidates for radiation therapy with curative intent.[25] Primary radiation therapy often consists of approximately 60 Gy delivered with megavoltage equipment to the midplane of the volume of the known tumor using conventional fractionation. A boost to the cone down field of the primary tumor is frequently used to enhance local control. Careful treatment planning with precise definition of target volume and avoidance of critical normal structures, to the extent possible, is needed for optimal results; this requires the use of a simulator.
Sources: 25
Among patients with excellent performance status, a 3-year survival rate of 20% may be expected if a course of radiation therapy with curative intent can be completed.
Evidence (radiation therapy):
In the largest retrospective series reported to date, 152 patients with medically inoperable NSCLC were treated with definitive radiation therapy. The study reported the following:[26]
Sources: 26
In the largest retrospective series reported to date, 152 patients with medically inoperable NSCLC were treated with definitive radiation therapy. The study reported the following:[26]
A 5-year OS rate of 10%.
Forty-four patients with T1 tumors achieved an actuarial DFS rate of 60%.
This retrospective study also suggested that improved DFS was obtained with radiation therapy doses greater than 60 Gy.[26]
Sources: 26
Treatment of Stage IIIA NSCLC
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Patients with stage IIIA non-small cell lung cancer (NSCLC) are a heterogenous group. Patients may have metastases to ipsilateral mediastinal nodes, potentially resectable T3 tumors invading the chest wall, or mediastinal involvement with metastases to peribronchial or hilar lymph nodes (N1). Presentations of disease range from resectable tumors with microscopic metastases to lymph nodes to unresectable, bulky disease involving multiple nodal stations.
Patients with clinical stage IIIA N2 disease have a 5-year overall survival (OS) rate of 10% to 15%; however, patients with bulky mediastinal involvement (i.e., visible on chest radiography) have a 5-year survival rate of 2% to 5%. Depending on clinical circumstances, the principal forms of treatment that are considered for patients with stage IIIA NSCLC are radiation therapy, chemotherapy, surgery, and combinations of these modalities.
Treatment options vary according to the location of the tumor and whether it is resectable.
Treatment Options for Resected/Resectable Stage IIIA NSCLC
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Treatment options for resected/resectable disease include:
Surgery with neoadjuvant or adjuvant therapy.
Neoadjuvant therapy.
Sources: Neoadjuvant therapy
Neoadjuvant chemoradiation therapy.
Sources: Neoadjuvant chemoradiation therapy
Neoadjuvant immunotherapy with chemotherapy.
Neoadjuvant therapy. › Neoadjuvant immunotherapy with chemotherapy.
Nivolumab plus platinum-based chemotherapy.
Perioperative (neoadjuvant and adjuvant) immunotherapy with chemotherapy.
Sources: Perioperative (neoadjuvant and adjuvant) immunotherapy with chemotherapy
Perioperative (neoadjuvant and adjuvant) immunotherapy with chemotherapy.
Perioperative pembrolizumab plus platinum-based chemotherapy.
Sources: Perioperative pembrolizumab plus platinum-based chemotherapy
Perioperative durvalumab plus platinum-based chemotherapy.
Sources: Perioperative durvalumab plus platinum-based chemotherapy
Perioperative nivolumab plus platinum-based chemotherapy.
Sources: Perioperative nivolumab plus platinum-based chemotherapy
Perioperative toripalimab plus platinum-based chemotherapy.
Sources: Perioperative toripalimab plus platinum-based chemotherapy
Adjuvant therapy.
Sources: Adjuvant therapy
Adjuvant targeted therapy (for patients with EGFR variants).
Sources: Adjuvant targeted therapy
Adjuvant targeted therapy (for patients with ALK variants).
Sources: Adjuvant targeted therapy
Adjuvant immunotherapy.
Sources: Adjuvant immunotherapy
Adjuvant chemoradiation therapy.
Sources: Adjuvant chemoradiation therapy
Adjuvant radiation therapy.
Sources: Adjuvant radiation therapy
Despite careful preoperative staging, some patients will be found to have metastases to mediastinal N2 lymph nodes at thoracotomy.
The preponderance of evidence indicates that postoperative cisplatin combination chemotherapy provides a significant survival advantage to patients with resected NSCLC with occult N2 disease discovered at surgery. The optimal sequence of surgery and chemotherapy and the benefits and risks of postoperative radiation therapy in patients with resectable NSCLC are yet to be determined.
Surgery
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
If complete resection of tumor and lymph nodes is possible, such patients may benefit from surgery followed by postoperative chemotherapy. Current evidence suggests that lung cancer resection combined with complete ipsilateral mediastinal lymph node dissection (CMLND) is not associated with improvement in survival compared with lung cancer resection combined with systematic sampling of mediastinal lymph nodes in patients with stage I, II, or IIIA NSCLC.[1][Level of evidence A1]
Sources: 1 · Level of evidence A1
The addition of surgery to chemoradiation therapy for patients with stage IIIA NSCLC did not result in improved OS in a phase III trial but did improve progression-free survival (PFS) and local control.[2][Level of evidence B1]
Sources: 2 · Level of evidence B1
Evidence (surgery):
The Cochrane Collaboration reviewed 11 randomized trials with a total of 1,910 patients who underwent surgical interventions for early-stage (I–IIIA) lung cancer.[3] A pooled analysis of three trials reported the following:
Sources: 3
The Cochrane Collaboration reviewed 11 randomized trials with a total of 1,910 patients who underwent surgical interventions for early-stage (I–IIIA) lung cancer.[3] A pooled analysis of three trials reported the following:
Four-year survival was superior in patients with resectable stage I, II, or IIIA NSCLC who underwent resection and CMLND, compared with those who underwent resection and lymph node sampling; the hazard ratio (HR) was estimated to be 0.78 (95% confidence interval [CI], 0.65–0.93; P = .005).[3][Level of evidence A1]
Sources: 3 · Level of evidence A1
CMLND versus lymph node sampling was evaluated in a large randomized phase III trial (ACOSOG-Z0030). Preliminary analyses of operative morbidity and mortality showed comparable rates from the procedures.[4]
Sources: ACOSOG-Z0030 · 4
CMLND versus lymph node sampling was evaluated in a large randomized phase III trial (ACOSOG-Z0030). Preliminary analyses of operative morbidity and mortality showed comparable rates from the procedures.[4]
There was no difference in OS, disease-free survival (DFS), local recurrence, and regional recurrence.[1][Level of evidence A1]
Sources: 1 · Level of evidence A1
Conclusions about the efficacy of surgery for patients with local and locoregional NSCLC are limited by the small number of participants studied to date and by the potential methodological weaknesses of the trials.
Neoadjuvant therapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Neoadjuvant chemotherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
The role of chemotherapy before surgery in patients with stage IIIA NSCLC has been extensively tested in clinical trials. The proposed benefits of preoperative (neoadjuvant) chemotherapy include:
A reduction in tumor size that may facilitate surgical resection.
Early eradication of micrometastases.
Better tolerability.
Evidence (neoadjuvant chemotherapy):
The Cochrane Collaboration provided a systematic review and meta-analysis of seven randomized controlled trials that included 988 patients and evaluated the addition of preoperative chemotherapy to surgery versus surgery alone.[5] These trials evaluated patients with stages I, II, and IIIA NSCLC.
Sources: 5
The Cochrane Collaboration provided a systematic review and meta-analysis of seven randomized controlled trials that included 988 patients and evaluated the addition of preoperative chemotherapy to surgery versus surgery alone.[5] These trials evaluated patients with stages I, II, and IIIA NSCLC.
Preoperative chemotherapy provided an absolute benefit in survival of 6% across all stages of disease, from 14% to 20% at 5 years (HR, 0.82; 95% CI, 0.69–0.97; P = .022).[5][Level of evidence A1]
Sources: 5 · Level of evidence A1
This analysis was unable to address questions such as whether particular types of patients may benefit more or less from preoperative chemotherapy.[6]
Sources: 6
In the largest trial reported to date, 519 patients were randomly assigned to receive either surgery alone or three cycles of platinum-based chemotherapy followed by surgery.[7] Most patients (61%) had clinical stage I disease, 31% had stage II disease, and 7% had stage III disease.
Sources: 7
In the largest trial reported to date, 519 patients were randomly assigned to receive either surgery alone or three cycles of platinum-based chemotherapy followed by surgery.[7] Most patients (61%) had clinical stage I disease, 31% had stage II disease, and 7% had stage III disease.
Postoperative complications were similar between groups, and no impairment of quality of life was observed.
There was no evidence of a benefit in terms of OS (HR, 1.02; 95% CI, 0.80–1.31; P = .86).
Updating the systematic review by addition of the present result suggests a 12% relative survival benefit with the addition of preoperative chemotherapy (1,507 patients; HR, 0.88; 95% CI, 0.76–1.01; P = .07), equivalent to an absolute improvement in survival of 5% at 5 years.[7]
Sources: 7
Neoadjuvant chemoradiation therapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Administering concurrent neoadjuvant chemotherapy and radiation therapy before surgery may intensify treatment and increase the likelihood of downstaging the tumor burden. Commonly used regimens that have been tested in the phase II setting include cisplatin/etoposide (EP5050) and weekly carboplatin/paclitaxel.[8,9] In a randomized trial of neoadjuvant chemoradiation therapy and surgery versus concurrent chemoradiation therapy alone, there was no difference in OS, but surgery improved PFS and local control.[2][Level of evidence B1]
Sources: 8 · 9 · 2 · Level of evidence B1
Evidence (neoadjuvant chemoradiation therapy):
The Intergroup-0139 trial (NCT00002550) compared chemoradiation therapy alone with neoadjuvant chemoradiation followed by surgery in 396 patients with stage IIIA (N2) NSCLC.[2]
Sources: Intergroup-0139 · 2
The Intergroup-0139 trial (NCT00002550) compared chemoradiation therapy alone with neoadjuvant chemoradiation followed by surgery in 396 patients with stage IIIA (N2) NSCLC.[2]
Surgery did not improve OS (5-year OS rate, 27% vs. 20%; HR, 0.87; 0.70–1.10; P = .24).
Surgery improved PFS (5-year PFS rate, 22% vs. 11%; HR, 0.77; 0.62–0.96; P = .017) and decreased the risk of local recurrence (10% vs. 22%; P = .002).
There was increased treatment mortality with neoadjuvant chemoradiation with surgery (8% vs. 2%), particularly in the subset of patients who underwent pneumonectomy.
A direct comparison of neoadjuvant chemotherapy versus neoadjuvant chemoradiation therapy using modern treatment regimens has not been performed to date; the optimal neoadjuvant approach remains unclear.
Neoadjuvant immunotherapy with chemotherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Nivolumab plus platinum-based chemotherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
The CheckMate 816 trial evaluated the combination of nivolumab (an anti-programmed death 1 antibody) and platinum-based chemotherapy as neoadjuvant therapy in patients with resectable (≥4 cm or node positive) NSCLC. Nivolumab therapy improved event-free survival (EFS) and pathological complete response rates compared with chemotherapy alone.
Evidence (nivolumab plus platinum-based chemotherapy):
CheckMate 816 (NCT02998528) was a phase III open-label trial that enrolled 358 patients with resectable stage IB to stage IIIA NSCLC. Notably, patients with stage IB disease had tumors measuring at least 4 cm and were classified according to the American Joint Committee on Cancer (AJCC) 7th edition staging criteria used for this trial; these tumors are now classified as stage IIA according to the AJCC 8th edition staging criteria. Patients were randomly assigned to receive nivolumab (360 mg) in combination with platinum-doublet chemotherapy or platinum-doublet chemotherapy alone every 3 weeks for three cycles before undergoing definitive surgery. The primary end points were EFS (defined as the time from randomization to any progression of disease precluding surgery, progression or recurrence of disease after surgery, progression of disease in the absence of surgery, or death from any cause) and pathological complete response (defined as 0% residual viable tumor cells in the primary tumor and sampled lymph nodes) according to blinded independent central review.[10][Level of evidence B1]
Sources: CheckMate 816 · 10 · Level of evidence B1
CheckMate 816 (NCT02998528) was a phase III open-label trial that enrolled 358 patients with resectable stage IB to stage IIIA NSCLC. Notably, patients with stage IB disease had tumors measuring at least 4 cm and were classified according to the American Joint Committee on Cancer (AJCC) 7th edition staging criteria used for this trial; these tumors are now classified as stage IIA according to the AJCC 8th edition staging criteria. Patients were randomly assigned to receive nivolumab (360 mg) in combination with platinum-doublet chemotherapy or platinum-doublet chemotherapy alone every 3 weeks for three cycles before undergoing definitive surgery. The primary end points were EFS (defined as the time from randomization to any progression of disease precluding surgery, progression or recurrence of disease after surgery, progression of disease in the absence of surgery, or death from any cause) and pathological complete response (defined as 0% residual viable tumor cells in the primary tumor and sampled lymph nodes) according to blinded independent central review.[10][Level of evidence B1]
With a minimum follow-up of 21 months, the median EFS was 31.6 months (95% CI, 30.2–not reached [NR]) in the nivolumab-plus-chemotherapy group and 20.8 months (95% CI, 14.0–26.7) in the chemotherapy-alone group (HR, 0.63; 97.38% CI, 0.43–0.91; P = .005).
The estimated percentage of patients surviving without disease progression or disease recurrence at 1 year was 76.1% for patients who received nivolumab plus chemotherapy and 63.4% for patients who received chemotherapy alone. The magnitude of benefit was greater in 1) patients with stage IIIA disease versus patients with stage IB or II disease (HR, 0.54; 95% CI, 0.37–0.80 vs. HR, 0.87; 95% CI, 0.48–1.56), 2) patients with tumor programmed death-ligand 1 (PD-L1) expression ≥1% versus <1% (HR, 0.41; 95% CI, 0.24–0.70 vs. HR, 0.85; 95% CI, 0.54–1.32), and 3) patients with nonsquamous histology versus squamous histology.
Pathological complete response was observed in 24% (95% CI, 18.0%– 31.0%) of patients who received nivolumab plus chemotherapy and 2.2% (95% CI, 0.6%–5.6%) of patients who received chemotherapy alone (odds ratio, 13.94; 99% CI, 3.49–55.75; P < .001).
Median OS was not reached in either group (HRdeath, 0.57; 99.67% CI, 0.30–1.07; P = .008).
Grade 3 or 4 treatment-related adverse events occurred in 33.5% of patients in the nivolumab-plus-chemotherapy group and in 36.9% of patients in the chemotherapy-alone group. Treatment-related adverse events led to treatment discontinuation in 10.2% of patients in the nivolumab-plus-chemotherapy group and in 9.7% of patients in the chemotherapy-alone group.
NADIM (NCT03081689) was an open-label, multicenter, single-arm trial for patients with stage IIIA NSCLC with surgically resectable disease. Patients received neoadjuvant paclitaxel and carboplatin plus nivolumab (360 mg) every 21 days for three cycles, followed by adjuvant nivolumab monotherapy for 1 year (240 mg once every 2 weeks for 4 months, followed by 480 mg once every 4 weeks for 8 months). The intention-to-treat (ITT) population included all patients who received neoadjuvant treatment. The per-protocol population included all patients who underwent tumor resection and received at least one cycle of adjuvant therapy. The median follow-up time was 60 months.[11,12]Circulating tumor DNA (ctDNA) from plasma samples obtained before and after neoadjuvant treatment (but before surgery) was analyzed with the hybridization capture–based TruSight Oncology 500 ctDNA next-generation sequencing assay on a NovaSeq sequencer (Illumina).
NADIM (NCT03081689) was an open-label, multicenter, single-arm trial for patients with stage IIIA NSCLC with surgically resectable disease. Patients received neoadjuvant paclitaxel and carboplatin plus nivolumab (360 mg) every 21 days for three cycles, followed by adjuvant nivolumab monotherapy for 1 year (240 mg once every 2 weeks for 4 months, followed by 480 mg once every 4 weeks for 8 months). The intention-to-treat (ITT) population included all patients who received neoadjuvant treatment. The per-protocol population included all patients who underwent tumor resection and received at least one cycle of adjuvant therapy. The median follow-up time was 60 months.[11,12]Circulating tumor DNA (ctDNA) from plasma samples obtained before and after neoadjuvant treatment (but before surgery) was analyzed with the hybridization capture–based TruSight Oncology 500 ctDNA next-generation sequencing assay on a NovaSeq sequencer (Illumina).
In the ITT population, the 5-year PFS rate was 65.0% (95% CI, 49.4%–76.9%), and the OS rate was 69.3% (53.7%–80.6%).[12][Level of evidence C1]
Sources: 12 · Level of evidence C1
Major pathological response was defined as the presence of 10% or fewer tumor cells in the primary tumor. A total of 82.9% of patients had a major pathological response, including 63.4% of patients who had a complete pathological response. A total of 17.1% patients had an incomplete response.
Disease progression occurred in 11 patients (24%).
A total of 14 patients (30%) died, including 9 (20%) of disease relapse and 5 (11%) of causes not related to the tumor.
Tumor mutational burden and PD-L1 status were not predictive of survival.
Low pretreatment levels of ctDNA were significantly associated with improved PFS (HR, 0.20; 95% CI, 0.06–0.63) and OS (HR, 0.07; 95% CI, 0.01–0.39).
Undetectable ctDNA levels after neoadjuvant treatment were significantly associated with PFS (HR, 0.26; 95% CI, 0.07–0.93) and OS (HR, 0.04; 95% CI, 0.00–0.55).
The U.S. Food and Drug Administration (FDA) approved nivolumab in combination with platinum-doublet chemotherapy for neoadjuvant treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC.
Perioperative (neoadjuvant and adjuvant) immunotherapy with chemotherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Several immune checkpoint inhibitors have been approved by the FDA for select patient populations with potentially resectable NSCLC, either in the neoadjuvant setting (nivolumab) or adjuvant setting (atezolizumab, durvalumab, or pembrolizumab). Ongoing phase III trials are evaluating the role of perioperative immune checkpoint inhibitors. These regimens for patients with potentially resectable stages II to III NSCLC include neoadjuvant immune checkpoint inhibitors with chemotherapy followed by surgery and adjuvant immune checkpoint inhibitors. Compared with neoadjuvant chemotherapy alone, early results from studies of perioperative immune checkpoint inhibitor regimens have shown improvements in several key outcomes including EFS, major pathological response, pathological complete response, and OS.
Perioperative pembrolizumab plus platinum-based chemotherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Evidence (neoadjuvant pembrolizumab plus chemotherapy and adjuvant pembrolizumab):
The phase III double-blind KEYNOTE-671 (NCT03425643) trial included 797 patients with untreated stage II, IIIA, or IIIB (≥1 ipsilateral mediastinal node or subcarinal node) NSCLC. Patients were randomly assigned to receive neoadjuvant pembrolizumab (200 mg every 3 weeks) or placebo with cisplatin-based chemotherapy for four cycles, followed by surgery and adjuvant pembrolizumab or placebo for up to 13 cycles, or until disease progression or unacceptable toxicity. The dual primary end points were EFS (defined as the time from randomization to local progression precluding surgery, unresectable tumor, progression or recurrence, or death) and OS. At the second interim analysis, the median follow-up was 36.6 months (range, 27.6–47.8).[13][Level of evidence A1]
Sources: KEYNOTE-671 · 13 · Level of evidence A1
The phase III double-blind KEYNOTE-671 (NCT03425643) trial included 797 patients with untreated stage II, IIIA, or IIIB (≥1 ipsilateral mediastinal node or subcarinal node) NSCLC. Patients were randomly assigned to receive neoadjuvant pembrolizumab (200 mg every 3 weeks) or placebo with cisplatin-based chemotherapy for four cycles, followed by surgery and adjuvant pembrolizumab or placebo for up to 13 cycles, or until disease progression or unacceptable toxicity. The dual primary end points were EFS (defined as the time from randomization to local progression precluding surgery, unresectable tumor, progression or recurrence, or death) and OS. At the second interim analysis, the median follow-up was 36.6 months (range, 27.6–47.8).[13][Level of evidence A1]
The median EFS was 47.2 months (95% CI, 32.9–NR) in the pembrolizumab group and 18.3 months (95% CI, 14.8–22.1) in the placebo group (HR, 0.59; 95% CI, 0.48–0.72).
The 36-month OS rate estimates were 71% (95% CI, 66%–76%) in the pembrolizumab group and 64% (95% CI, 58%–69%) in the placebo group (HR, 0.72; 95% CI, 0.56–0.93; one-sided P = .0052; threshold, one-sided P = .0054).
Secondary end points were reported as follows:
The phase III double-blind KEYNOTE-671 (NCT03425643) trial included 797 patients with untreated stage II, IIIA, or IIIB (≥1 ipsilateral mediastinal node or subcarinal node) NSCLC. Patients were randomly assigned to receive neoadjuvant pembrolizumab (200 mg every 3 weeks) or placebo with cisplatin-based chemotherapy for four cycles, followed by surgery and adjuvant pembrolizumab or placebo for up to 13 cycles, or until disease progression or unacceptable toxicity. The dual primary end points were EFS (defined as the time from randomization to local progression precluding surgery, unresectable tumor, progression or recurrence, or death) and OS. At the second interim analysis, the median follow-up was 36.6 months (range, 27.6–47.8).[13][Level of evidence A1] › Secondary end points were reported as follows:
Major pathological response occurred in 30.2% of patients in the pembrolizumab group and 11.0% of patients in the placebo group (P < .0001).
Pathological complete response occurred in 18.1% of patients in the pembrolizumab group and 4.0% of patients in the placebo group (P < .0001).
The phase III double-blind KEYNOTE-671 (NCT03425643) trial included 797 patients with untreated stage II, IIIA, or IIIB (≥1 ipsilateral mediastinal node or subcarinal node) NSCLC. Patients were randomly assigned to receive neoadjuvant pembrolizumab (200 mg every 3 weeks) or placebo with cisplatin-based chemotherapy for four cycles, followed by surgery and adjuvant pembrolizumab or placebo for up to 13 cycles, or until disease progression or unacceptable toxicity. The dual primary end points were EFS (defined as the time from randomization to local progression precluding surgery, unresectable tumor, progression or recurrence, or death) and OS. At the second interim analysis, the median follow-up was 36.6 months (range, 27.6–47.8).[13][Level of evidence A1]
Grade 3 to 5 treatment-related adverse events occurred in 179 of 396 patients (45%) in the pembrolizumab group and in 151 of 399 patients (38%) in the placebo group. Treatment-related adverse events led to death in four patients (1%) in the pembrolizumab group and three patients (1%) in the placebo group.
Perioperative durvalumab plus platinum-based chemotherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Evidence (durvalumab plus platinum-based chemotherapy):
The phase III AEGEAN trial (NCT03800134) investigated perioperative durvalumab plus neoadjuvant chemotherapy compared with neoadjuvant chemotherapy alone in patients with resectable (stage II to IIIB [N2]) NSCLC. Patients received four cycles of treatment every 3 weeks before surgery, followed by adjuvant durvalumab or placebo intravenously every 4 weeks for 12 cycles. The modified intention-to-treat population (740 patients) included all patients who were randomly assigned, excluding patients with documented EGFR or ALK alterations. The first planned interim analysis occurred with 31.9% data maturity and at a median follow-up of 1 year. The primary end points were EFS and pathological complete response.[14][Level of evidence B1]
Sources: AEGEAN · 14 · Level of evidence B1
The phase III AEGEAN trial (NCT03800134) investigated perioperative durvalumab plus neoadjuvant chemotherapy compared with neoadjuvant chemotherapy alone in patients with resectable (stage II to IIIB [N2]) NSCLC. Patients received four cycles of treatment every 3 weeks before surgery, followed by adjuvant durvalumab or placebo intravenously every 4 weeks for 12 cycles. The modified intention-to-treat population (740 patients) included all patients who were randomly assigned, excluding patients with documented EGFR or ALK alterations. The first planned interim analysis occurred with 31.9% data maturity and at a median follow-up of 1 year. The primary end points were EFS and pathological complete response.[14][Level of evidence B1]
At 12 months, the EFS rate was 73.4% for patients who received durvalumab (95% CI, 67.9%–78.1%), and 64.5% for patients who received chemotherapy alone (95% CI, 58.8%–69.6%).
Pathological complete response was significantly higher with perioperative durvalumab (17.2%), compared with chemotherapy alone (4.3%, P < .001).
The EFS and pathological complete response benefit were observed regardless of stage and PD-L1 expression.
The safety profile was consistent with known profiles of durvalumab and chemotherapy.
Perioperative nivolumab plus platinum-based chemotherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Evidence (neoadjuvant nivolumab plus chemotherapy and adjuvant nivolumab):
Checkmate 77T (NCT04025879) was a phase III double-blind trial that enrolled 735 patients with resectable stage IIA (>4 cm) to IIIB (N2 node stage, single- or multistation) NSCLC. Patients had no EGFR variants or known ALK translocations. Patients were randomly assigned to receive either neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo every 3 weeks for four cycles, followed by surgery and adjuvant nivolumab or placebo every 4 weeks for 1 year. The primary end point was EFS according to blinded independent review. Secondary end points were pathological complete response and major pathological response according to blinded independent review, OS, and safety.[15]
Sources: Checkmate 77T · 15
Checkmate 77T (NCT04025879) was a phase III double-blind trial that enrolled 735 patients with resectable stage IIA (>4 cm) to IIIB (N2 node stage, single- or multistation) NSCLC. Patients had no EGFR variants or known ALK translocations. Patients were randomly assigned to receive either neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo every 3 weeks for four cycles, followed by surgery and adjuvant nivolumab or placebo every 4 weeks for 1 year. The primary end point was EFS according to blinded independent review. Secondary end points were pathological complete response and major pathological response according to blinded independent review, OS, and safety.[15]
At median follow-up of 25.4 months (range, 15.7–44.2), the 18-month EFS rate was 70.2% in the nivolumab group and 50.0% in the chemotherapy group (HRdisease progression or recurrence, abandoned surgery, or death, 0.58; 97.36% CI, 0.42–0.81; P < .001).[15][Level of evidence B1]
Sources: 15 · Level of evidence B1
The pathological complete response rate was 25.3% in the nivolumab group and 4.7% in the chemotherapy group (OR, 6.64; 95% CI, 3.40–12.97).
The major pathological response rate (≤10% residual viable tumor cells after surgery in the primary tumor and sampled lymph nodes) was 35.4% in the nivolumab group and 12.1% in the chemotherapy group (OR, 4.01; 95% CI, 2.48–6.49).
Grade 3 or 4 treatment-related adverse events occurred in 32.5% of patients in the nivolumab group and 25.2% of patients in the chemotherapy group.
Perioperative toripalimab plus platinum-based chemotherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Evidence (toripalimab plus platinum-based chemotherapy):
A phase III randomized trial (Neotorch [NCT04158440]) evaluated the efficacy and safety of toripalimab in combination with neoadjuvant platinum-based chemotherapy followed by maintenance toripalimab versus chemotherapy alone in patients with resectable stage II, IIIA, or IIIB (N2) NSCLC without EGFR or ALK alterations. Patients were stratified by disease stage (II, IIIA, or IIIB), PD-L1 tumor expression status (≥1%, <1%, or not evaluable using the JS311IHC staining assay), planned surgical approach (pneumonectomy or lobectomy), and histological subtype (squamous vs. nonsquamous). A total of 501 patients with stage II to III resectable NSCLC were randomly assigned to receive either (1) toripalimab plus platinum-based chemotherapy for three cycles before surgery and one cycle after surgery followed by single-agent maintenance toripalimab for up to 13 cycles or (2) platinum-based chemotherapy alone for three cycles before surgery and one cycle after surgery. Coprimary end points were EFS (defined as time from randomization to the first documentation of disease progression leading to the inability to operate, postoperative progression, or local or distant recurrence/death from any cause) and major pathological response (≤10% or less viable tumor cells in the tumor bed). Secondary end points included OS, pathological complete response, DFS after surgery, and safety.[16]
A phase III randomized trial (Neotorch [NCT04158440]) evaluated the efficacy and safety of toripalimab in combination with neoadjuvant platinum-based chemotherapy followed by maintenance toripalimab versus chemotherapy alone in patients with resectable stage II, IIIA, or IIIB (N2) NSCLC without EGFR or ALK alterations. Patients were stratified by disease stage (II, IIIA, or IIIB), PD-L1 tumor expression status (≥1%, <1%, or not evaluable using the JS311IHC staining assay), planned surgical approach (pneumonectomy or lobectomy), and histological subtype (squamous vs. nonsquamous). A total of 501 patients with stage II to III resectable NSCLC were randomly assigned to receive either (1) toripalimab plus platinum-based chemotherapy for three cycles before surgery and one cycle after surgery followed by single-agent maintenance toripalimab for up to 13 cycles or (2) platinum-based chemotherapy alone for three cycles before surgery and one cycle after surgery. Coprimary end points were EFS (defined as time from randomization to the first documentation of disease progression leading to the inability to operate, postoperative progression, or local or distant recurrence/death from any cause) and major pathological response (≤10% or less viable tumor cells in the tumor bed). Secondary end points included OS, pathological complete response, DFS after surgery, and safety.[16]
In a prespecified interim analysis of EFS in patients with stage III NSCLC (n = 404) after a median follow-up of 18.3 months (IQR, 12.7–22.5 months), the median EFS was not reached (95% CI, 24.4 months–NR) in the toripalimab group and was 15.1 months (95% CI, 10.6–21.9) in the placebo group (HR, 0.40; 95% CI, 0.28–0.57; P < .001).
The 1- and 2-year EFS rates were 84.4% and 64.7%, respectively, in the toripalimab group and 57.0% and 38.7%, respectively, in the placebo group. A consistent effect on EFS, favoring toripalimab, was observed in all subgroups.
After surgical resection, a major pathological response occurred in 98 patients (48.5%) in the toripalimab group and 17 patients (8.4%) in the placebo group (between group difference, 40.2%; 95% CI, 32.2%–48.1%; P < .001).
The FDA has not approved this drug for patients with lung cancer.
Adjuvant therapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Adjuvant chemotherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Patients with completely resected stage IIIA NSCLC may benefit from postoperative cisplatin-based chemotherapy.[17][Level of evidence A1]
Sources: 17 · Level of evidence A1
Evidence (adjuvant chemotherapy):
Evidence from randomized controlled clinical trials indicates that when stage IIIA NSCLC is encountered unexpectedly at surgery, chemotherapy given after complete resection improves survival.
Several randomized, controlled trials and meta-analyses have evaluated the use of postoperative chemotherapy in patients with stages I, II, and IIIA NSCLC.[17-23]
Data on individual patient outcomes from the five largest trials (4,584 patients) that were conducted after 1995 of cisplatin-based chemotherapy in patients with completely resected NSCLC were collected and pooled into a meta-analysis.[17]
Sources: 17
Data on individual patient outcomes from the five largest trials (4,584 patients) that were conducted after 1995 of cisplatin-based chemotherapy in patients with completely resected NSCLC were collected and pooled into a meta-analysis.[17]
With a median follow-up of 5.2 years, the overall HRdeath was 0.89 (95% CI, 0.82–0.96; P = .005), corresponding to a 5-year absolute benefit of 5.4% from chemotherapy.
The effect of chemotherapy did not vary significantly (test for interaction, P = .11) with the associated drugs, including vinorelbine (HR, 0.80; 95% CI, 0.70–0.91), etoposide or vinca alkaloid (HR, 0.92; 95% CI, 0.80–1.07), or other drugs (HR, 0.97; 95% CI, 0.84–1.13).
The benefit varied with stage (HR for stage IIIA, 0.83; 95% CI, 0.72–0.94).
The greater effect on survival observed with the doublet of cisplatin plus vinorelbine compared with other regimens should be interpreted with caution as the total dose of cisplatin received was significantly higher in patients treated with vinorelbine.
Two trials (FRE-IALT and the Adjuvant Navelbine International Trialist Association [ANITA] trial) reported significant OS benefits associated with postoperative chemotherapy in stage IIIA disease.[6,19]
Two trials (FRE-IALT and the Adjuvant Navelbine International Trialist Association [ANITA] trial) reported significant OS benefits associated with postoperative chemotherapy in stage IIIA disease.[6,19]
For the subgroup of stage IIIA patients in the ANITA trial (n = 325), the HR was 0.69 (95% CI, 0.53–0.90), and the result for the FRE-IALT trial (n = 728) was HR, 0.79 (95% CI, 0.66–0.95).
The chemotherapy effect was higher in patients with a better performance status.
There was no interaction between the chemotherapy effect and any of the following:
Two trials (FRE-IALT and the Adjuvant Navelbine International Trialist Association [ANITA] trial) reported significant OS benefits associated with postoperative chemotherapy in stage IIIA disease.[6,19] › There was no interaction between the chemotherapy effect and any of the following:
Sex.
Age.
Histology.
Type of surgery.
Planned radiation therapy.
Planned total dose of cisplatin.
In a retrospective analysis of a phase III trial of postoperative cisplatin and vinorelbine, patients older than 65 years were found to benefit from treatment.[24]
Sources: 24
In a retrospective analysis of a phase III trial of postoperative cisplatin and vinorelbine, patients older than 65 years were found to benefit from treatment.[24]
Chemotherapy significantly prolonged OS for patients older than 65 years (HR, 0.61; 95% CI, 0.38–0.98; P = .04).
There were no significant differences in toxic effects, hospitalization, or treatment-related death by age group, although patients older than 65 years received less treatment.
Adjuvant targeted therapy (for patients with EGFR variants)
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Adjuvant targeted therapy with osimertinib for patients with resected stage IB to IIIA NSCLC and an EGFR pathogenic variant was studied in a phase III clinical trial and showed improved OS.
Evidence (adjuvant targeted therapy with osimertinib for patients with stage IIIA NSCLC and an EGFR variant):
The phase III, double-blind, placebo-controlled ADAURA (NCT02511106) trial included 682 patients with surgically resected stage IB to stage IIIA NSCLC and EGFR pathogenic variants (centrally determined, deletion in exon 19 or L858R variant). Patients were randomly assigned to receive 80 mg of osimertinib by mouth daily (n = 399) or a placebo (n = 342) for 3 years. Standard postoperative adjuvant chemotherapy was allowed but not mandatory; decisions regarding adjuvant chemotherapy were made by the physician and patient before trial enrollment.[25][Level of evidence A1]
Sources: ADAURA · 25 · Level of evidence A1
The phase III, double-blind, placebo-controlled ADAURA (NCT02511106) trial included 682 patients with surgically resected stage IB to stage IIIA NSCLC and EGFR pathogenic variants (centrally determined, deletion in exon 19 or L858R variant). Patients were randomly assigned to receive 80 mg of osimertinib by mouth daily (n = 399) or a placebo (n = 342) for 3 years. Standard postoperative adjuvant chemotherapy was allowed but not mandatory; decisions regarding adjuvant chemotherapy were made by the physician and patient before trial enrollment.[25][Level of evidence A1]
In the overall population, the 5-year OS rate was 88% in the osimertinib group and 78% in the placebo group (overall HRdeath, 0.49; 95.03% CI, 0.34–0.70; P < .001).
Among patients with stage II to IIIA disease, the 5-year OS rate was 85% in the osimertinib group and 73% in the placebo group (overall HRdeath, 0.49; 95.03% CI, 0.33–0.73; P < .001).
The adverse event profile is consistent with other studies that used osimertinib except for pneumonia related to COVID-19, which was reported later.
The FDA approved osimertinib as adjuvant therapy for patients with stage IB to IIIA NSCLC with EGFR exon 19 deletions or EGFR L858R variants.
Adjuvant targeted therapy (for patients with ALK variants)
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Evidence (adjuvant targeted therapy for patients with ALK variants).
The global, phase III, open-label ALINA trial (NCT03456076) included 257 patients with completely resected stage IB (tumors ≥4 cm), II, or IIIA (AJCC 7th edition staging criteria) NSCLC and an ALK variant. Patients were randomly assigned in a 1:1 ratio to receive either oral alectinib (600 mg twice daily) for 24 months or intravenous platinum-based chemotherapy in four 21-day cycles. The primary end point was DFS, tested hierarchically among patients with stage II or IIIA disease and then in the ITT population. Secondary end points included central nervous system (CNS) DFS, OS, and safety.[26]
The global, phase III, open-label ALINA trial (NCT03456076) included 257 patients with completely resected stage IB (tumors ≥4 cm), II, or IIIA (AJCC 7th edition staging criteria) NSCLC and an ALK variant. Patients were randomly assigned in a 1:1 ratio to receive either oral alectinib (600 mg twice daily) for 24 months or intravenous platinum-based chemotherapy in four 21-day cycles. The primary end point was DFS, tested hierarchically among patients with stage II or IIIA disease and then in the ITT population. Secondary end points included central nervous system (CNS) DFS, OS, and safety.[26]
The median duration of follow-up for survival was 27.8 months (27.8 months in the alectinib group and 28.4 months in the chemotherapy group).
The 2-year DFS rate was 93.8% in the alectinib group and 63.0% in the chemotherapy group (stage II/IIIA) (HRdisease recurrence or death, 0.24; 95% CI, 0.13–0.45; P < .001).[26][Level of evidence B1]
Sources: 26 · Level of evidence B1
The ITT population included patients with stage IB, II, or IIIA disease who had been randomly assigned. The DFS rate in the ITT population was 93.6% for patients who received alectinib and 63.7% for patients who received chemotherapy (HR, 0.24; 95% CI, 0.13–0.43; P < .001).
The HRCNS disease recurrence or death was 0.22 (95% CI, 0.08–0.58) in favor of alectinib.
OS data are immature.
The FDA approved alectinib for adjuvant treatment following tumor resection in patients with NSCLC and an ALK variant.
Adjuvant immunotherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Adjuvant immunotherapy for patients with resected stage IB to IIIA NSCLC has been found to significantly increase DFS.[27,28]
Evidence (adjuvant immunotherapy with pembrolizumab for patients with stage IIIA NSCLC):
The phase III, multicenter, open-label PEARLS/KEYNOTE-091 trial (NCT02504372) randomly assigned 1,177 patients with completely resected stage IB (tumor >4 cm) to stage IIIA NSCLC to receive pembrolizumab (200 mg every 3 weeks) or placebo for up to 18 cycles, or until disease progression, or unacceptable toxicity. Patients started study treatment after resection or, if indicated, after adjuvant chemotherapy (maximum of four cycles). The dual primary end points were DFS in the overall study population and DFS in patients with a PD-L1 tumor proportion score (TPS) of 50% or greater, as determined using the PD-L1 IHC 22C3 pharmDx assay. These end points were reported in a prespecified interim analysis after a median follow-up of 35.6 months (interquartile range, 27.1–45.5).[27][Level of evidence B1]
Sources: PEARLS/KEYNOTE-091 · 27 · Level of evidence B1
The phase III, multicenter, open-label PEARLS/KEYNOTE-091 trial (NCT02504372) randomly assigned 1,177 patients with completely resected stage IB (tumor >4 cm) to stage IIIA NSCLC to receive pembrolizumab (200 mg every 3 weeks) or placebo for up to 18 cycles, or until disease progression, or unacceptable toxicity. Patients started study treatment after resection or, if indicated, after adjuvant chemotherapy (maximum of four cycles). The dual primary end points were DFS in the overall study population and DFS in patients with a PD-L1 tumor proportion score (TPS) of 50% or greater, as determined using the PD-L1 IHC 22C3 pharmDx assay. These end points were reported in a prespecified interim analysis after a median follow-up of 35.6 months (interquartile range, 27.1–45.5).[27][Level of evidence B1]
In the overall study population, the median DFS was 53.6 months (95% CI, 39.2 to NR) in the pembrolizumab group and 42.0 months (95% CI, 31.3–NR) in the placebo group (HR, 0.76; 95% CI, 0.63–0.91, P = .0014).
In the PD-L1 TPS ≥50% population, the median DFS was not reached with either pembrolizumab (95% CI, 44.3–NR) or placebo (95% CI, 35.8–NR) (HR, 0.82; 95% CI, 0.57–1.18; P = .14).
OS data were immature at the time of prespecified interim analysis.
No new safety signals were identified in this study.
The FDA approved pembrolizumab as a single agent for adjuvant treatment following resection and platinum-based chemotherapy for patients with stage IB (T2a ≥4 cm), II, or IIIA NSCLC. Of note, the FDA label specifies that pembrolizumab can be used as adjuvant therapy after platinum-based chemotherapy. However, chemotherapy was not required in the overall study patient population evaluated in KEYNOTE-091.
Evidence (adjuvant immunotherapy with atezolizumab for patients with resected stage IIIA NSCLC):
IMpower010 (NCT02486718) was a phase III, multicenter, open-label trial that randomly assigned 1,005 patients with surgically resected stage IB (tumor >4 cm) to stage IIIA NSCLC. Patients received atezolizumab (1,200 mg every 21 days intravenously) or best supportive care for 16 cycles or 1 year after standard adjuvant platinum-based chemotherapy. Patients were enrolled after resection if they were eligible for cisplatin-based chemotherapy and were randomized after completion of chemotherapy if they remained eligible and did not experience disease progression. The primary end point was investigator-assessed DFS.[28]
Sources: IMpower010 · 28
IMpower010 (NCT02486718) was a phase III, multicenter, open-label trial that randomly assigned 1,005 patients with surgically resected stage IB (tumor >4 cm) to stage IIIA NSCLC. Patients received atezolizumab (1,200 mg every 21 days intravenously) or best supportive care for 16 cycles or 1 year after standard adjuvant platinum-based chemotherapy. Patients were enrolled after resection if they were eligible for cisplatin-based chemotherapy and were randomized after completion of chemotherapy if they remained eligible and did not experience disease progression. The primary end point was investigator-assessed DFS.[28]
The primary end point was tested hierarchically, first in the stage II to IIIA population subgroup whose tumors expressed PD-L1 on at least 1% of tumor cells (using the SP263 antibody), then in all patients in the stage II to IIIA population, and finally in the ITT population (stage IB to IIIA). Of the 882 patients who were randomly assigned and had stage II to IIIA disease, 476 had tumors expressing PD-L1 on at least 1% of tumor cells per SP263.[28][Level of evidence B1]
Sources: 28 · Level of evidence B1
After a median follow-up of 32.2 months, atezolizumab treatment improved DFS compared with best supportive care in patients in the stage II to IIIA population whose tumors expressed PD-L1 on at least 1% of tumor cells (HR, 0.66; 95% CI, 0.50–0.88; P = .0039). At 24 months, the DFS rate was 74.6% for the atezolizumab group and 61.0% for the best supportive care group.
Atezolizumab also improved DFS in all patients in the stage II to IIIA population (HR, 0.79; 95% CI, 0.64–0.96; P = .020). At 24 months, the DFS rate was 70.2% for the atezolizumab group and 61.6% for the best supportive care group.
In the ITT population, which included patients with stage IB to IIIA disease, HRDFS was 0.81 (95% CI, 0.67–0.99; P = .040). However, the boundary for statistical significance for DFS was not crossed.
OS data are immature.
No new safety signals were noted.
The FDA approved atezolizumab for adjuvant treatment of patients with stage II to IIIA NSCLC whose tumors express PD-L1 on at least 1% of tumor cells.
Adjuvant chemoradiation therapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Combination chemotherapy and radiation therapy administered before or following surgery should be viewed as investigational and requiring evaluation in future clinical trials.
Evidence (adjuvant chemoradiation therapy):
Five randomized trials have assessed the value of postoperative combination chemoradiation therapy versus radiation therapy following surgical resection.[5,7,29-31][Level of evidence A1]
Sources: 5 · 7 · 29 · 31 · Level of evidence A1
Five randomized trials have assessed the value of postoperative combination chemoradiation therapy versus radiation therapy following surgical resection.[5,7,29-31][Level of evidence A1]
Only one trial reported improved DFS, and no trial reported improved OS.
Three trials have evaluated platinum-based combination chemotherapy followed by surgery versus platinum-based chemotherapy followed by radiation therapy (60–69.6 Gy) alone to determine whether surgery or radiation therapy was most efficacious.[31-33] Although the studies were small, enrolling 73 (Radiation Therapy Oncology Group [RTOG]) (RTOG 89-01), 107 (The University of Texas M.D. Anderson Cancer Center), and 333 (European Organisation for Research and Treatment of Cancer [EORTC-08941; NCT00002623]) patients with stage IIIA (N2) disease, no trial reported a difference in local control or survival.[31-33][Level of evidence A1]
Sources: 31 · 33 · EORTC-08941 · 31 · 33 · Level of evidence A1
Three trials have evaluated platinum-based combination chemotherapy followed by surgery versus platinum-based chemotherapy followed by radiation therapy (60–69.6 Gy) alone to determine whether surgery or radiation therapy was most efficacious.[31-33] Although the studies were small, enrolling 73 (Radiation Therapy Oncology Group [RTOG]) (RTOG 89-01), 107 (The University of Texas M.D. Anderson Cancer Center), and 333 (European Organisation for Research and Treatment of Cancer [EORTC-08941; NCT00002623]) patients with stage IIIA (N2) disease, no trial reported a difference in local control or survival.[31-33][Level of evidence A1]
In the largest series (EORTC-08941), 579 patients with histologically- or cytologically-proven stage IIIA (N2) NSCLC were given three cycles of platinum-based induction chemotherapy.[33] The 333 responding patients were subsequently randomly assigned to surgical resection or radiation therapy. Of the 154 patients (92%) who underwent surgery, 50% had a radical resection, 42% had a pathological downstaging, and 5% had a pathological complete response; 4% died after surgery. Postoperative (adjuvant) radiation therapy (PORT) was administered to 62 patients (40%) in the surgery arm. Among the 154 patients (93%) who received radiation therapy, overall compliance to the radiation therapy prescription was 55%, and grade 3 to 4 acute and late esophageal and pulmonary toxic effects occurred in 4% and 7% of patients; one patient died of radiation pneumonitis.
Sources: 33
Three trials have evaluated platinum-based combination chemotherapy followed by surgery versus platinum-based chemotherapy followed by radiation therapy (60–69.6 Gy) alone to determine whether surgery or radiation therapy was most efficacious.[31-33] Although the studies were small, enrolling 73 (Radiation Therapy Oncology Group [RTOG]) (RTOG 89-01), 107 (The University of Texas M.D. Anderson Cancer Center), and 333 (European Organisation for Research and Treatment of Cancer [EORTC-08941; NCT00002623]) patients with stage IIIA (N2) disease, no trial reported a difference in local control or survival.[31-33][Level of evidence A1] › In the largest series (EORTC-08941), 579 patients with histologically- or cytologically-proven stage IIIA (N2) NSCLC were given three cycles of platinum-based induction chemotherapy.[33] The 333 responding patients were subsequently randomly assigned to surgical resection or radiation therapy. Of the 154 patients (92%) who underwent surgery, 50% had a radical resection, 42% had a pathological downstaging, and 5% had a pathological complete response; 4% died after surgery. Postoperative (adjuvant) radiation therapy (PORT) was administered to 62 patients (40%) in the surgery arm. Among the 154 patients (93%) who received radiation therapy, overall compliance to the radiation therapy prescription was 55%, and grade 3 to 4 acute and late esophageal and pulmonary toxic effects occurred in 4% and 7% of patients; one patient died of radiation pneumonitis.
Median OS was 16.4 months for patients assigned to resection versus 17.5 months for patients assigned to radiation therapy; the 5-year OS rate was 15.7% for patients assigned to resection versus 14% for patients assigned to radiation therapy (HR, 1.06; 95% CI, 0.84–1.35).[33]
Sources: 33
Rates of PFS were also similar in both groups. In view of its low morbidity and mortality, it was concluded that radiation therapy should be considered the preferred locoregional treatment for these patients.[33]
Sources: 33
Adjuvant radiation therapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
The value of PORT has been assessed.[29] Although some studies suggest that PORT can improve local control for node-positive patients whose tumors were resected, it remains controversial whether it can improve survival. The optimal dose of thoracic PORT is not known at this time. Most studies cited used doses ranging from 30 Gy to 60 Gy, typically provided in 2 Gy to 2.5 Gy fractions.[29]
As referred to in the National Cancer Institute of Canada (NCIC) Clinical Trials Group JBR.10 study (NCT00002583), PORT may be considered in selected patients to reduce the risk of local recurrence, if any of the following are present:[24]
Sources: NCT00002583 · 24
Involvement of multiple nodal stations.
Extracapsular tumor spread.
Close or microscopically positive resection margins.
Evidence (adjuvant radiation therapy):
Evidence from one large meta-analysis, subset analyses of randomized trials, and one large population study suggest that PORT may reduce local recurrence. Results from these studies on the effect of PORT on OS are conflicting.
A meta-analysis of ten randomized trials that evaluated PORT versus surgery alone showed the following:
A meta-analysis of ten randomized trials that evaluated PORT versus surgery alone showed the following:
No difference in OS for the entire PORT group or for the subset of N2 patients.[19][Level of evidence A1]
Sources: 19 · Level of evidence A1
Results from a nonrandomized subanalysis of the ANITA trial, comparing 5-year OS in N2 patients who did or did not receive PORT, found the following:[6]
Sources: 6
Results from a nonrandomized subanalysis of the ANITA trial, comparing 5-year OS in N2 patients who did or did not receive PORT, found the following:[6]
Higher survival rates in patients who received radiation therapy in the observation arm (21% in patients who received PORT vs. 17% in patients who did not receive PORT) and in the chemotherapy arm (47% with PORT vs. 34% without PORT); however, statistical tests of comparison were not conducted.[6]
Sources: 6
Results from the Surveillance, Epidemiology, and End Results (SEER) Program [30] suggest the following:
Sources: 30
Results from the Surveillance, Epidemiology, and End Results (SEER) Program [30] suggest the following:
The large SEER retrospective study (N = 7,465) found superior survival rates associated with radiation therapy in N2 disease (HR, 0.855; 95% CI, 0.762–0.959).
There is benefit of PORT in stage IIIA (N2) disease, and the role of PORT in early stages of NSCLC should be clarified in ongoing phase III trials. Further analysis is needed to determine whether these outcomes can be modified with technical improvements, better definitions of target volumes, and limitation of cardiac volume in the radiation portals.[19]
Sources: 19
Treatment Options for Unresectable Stage IIIA NSCLC
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Treatment options for patients with unresectable stage IIIA NSCLC include:
Chemoradiation therapy.
Sources: Chemoradiation therapy
Radiation therapy.
Sources: Radiation therapy
Radiation therapy.
Locally advanced unresectable tumors.
Sources: Locally advanced unresectable tumors
Palliative treatment.
Sources: Palliative treatment
Chemoradiation therapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
The addition of sequential and concurrent chemotherapy to radiation therapy has been evaluated in prospective randomized trials and meta-analyses. Overall, concurrent treatment may provide the greatest benefit in survival with an increase in toxic effects.
Concomitant platinum-based radiation chemotherapy may improve survival of patients with locally advanced NSCLC. However, the available data are insufficient to accurately define the size of such a potential treatment benefit and the optimal schedule of chemotherapy.[34]
Sources: 34
Evidence (chemoradiation therapy):
A meta-analysis of patient data from 11 randomized clinical trials showed the following:[35]
Sources: 35
A meta-analysis of patient data from 11 randomized clinical trials showed the following:[35]
Cisplatin-based combinations plus radiation therapy resulted in a 10% reduction in the risk of death compared with radiation therapy alone.[35][Level of evidence A1]
Sources: 35 · Level of evidence A1
A meta-analysis of 13 trials (based on 2,214 evaluable patients) showed the following:[36]
Sources: 36
A meta-analysis of 13 trials (based on 2,214 evaluable patients) showed the following:[36]
The addition of concurrent chemotherapy to radical radiation therapy reduced the risk of death at 2 years (relative risk [RR], 0.93; 95% CI, 0.88–0.98; P = .01).
For the 11 trials with platinum-based chemotherapy, RR was 0.93 (95% CI, 0.87–0.99; P = .02).[36]
Sources: 36
A meta-analysis of individual data from 1,764 patients was based on nine trials and showed the following:[34]
Sources: 34
A meta-analysis of individual data from 1,764 patients was based on nine trials and showed the following:[34]
The HRdeath among patients treated with radiation therapy and chemotherapy compared with radiation therapy alone was 0.89 (95% CI, 0.81–0.98; P = .02), corresponding to an absolute benefit of chemotherapy of 4% at 2 years.
The combination of platinum with etoposide appeared to be more effective than platinum alone.
Concurrent versus sequential chemoradiation therapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
The results from two randomized trials (including RTOG-9410 [NCT01134861]) and a meta-analysis indicate that concurrent chemotherapy and radiation therapy may provide greater survival benefit, albeit with more toxic effects, than sequential chemotherapy and radiation therapy.[37-39][Level of evidence A1]
Sources: RTOG-9410 · 37 · 39 · Level of evidence A1
Evidence (concurrent vs. sequential chemoradiation therapy):
In the first trial, the combination of mitomycin C, vindesine, and cisplatin were given concurrently with split-course daily radiation therapy to 56 Gy compared with chemotherapy followed by continuous daily radiation therapy to 56 Gy.[37]
Sources: 37
In the first trial, the combination of mitomycin C, vindesine, and cisplatin were given concurrently with split-course daily radiation therapy to 56 Gy compared with chemotherapy followed by continuous daily radiation therapy to 56 Gy.[37]
Five-year OS rates favored concurrent therapy (27% vs. 9%).
Myelosuppression was greater among patients in the concurrent arm, but treatment-related mortality was less than 1% in both arms.[37]
Sources: 37
In the second trial, 610 patients were randomly assigned to sequential chemotherapy with cisplatin and vinblastine followed by 63 Gy of radiation therapy, concurrent chemoradiation therapy using the same regimen, or concurrent chemotherapy with cisplatin and etoposide with twice-daily radiation therapy.[39]
Sources: 39
In the second trial, 610 patients were randomly assigned to sequential chemotherapy with cisplatin and vinblastine followed by 63 Gy of radiation therapy, concurrent chemoradiation therapy using the same regimen, or concurrent chemotherapy with cisplatin and etoposide with twice-daily radiation therapy.[39]
Median and 5-year survival were superior in the concurrent chemotherapy with daily radiation therapy arm (17 months vs. 14.6 months and 16% vs. 10% for sequential regimen; P = .046).[39]
Sources: 39
Two smaller studies also reported OS results that favored concurrent over sequential chemotherapy and radiation, although the results did not reach statistical significance.[38,40][Level of evidence A1]
Sources: 38 · 40 · Level of evidence A1
A meta-analysis of three trials evaluated concurrent versus sequential treatment (711 patients).[36]
Sources: 36
A meta-analysis of three trials evaluated concurrent versus sequential treatment (711 patients).[36]
The analysis indicated a significant benefit of concurrent over sequential treatment (RR, 0.86; 95% CI, 0.78–0.95; P = .003). All studies used cisplatin-based regimens and once-daily radiation therapy.[36]
Sources: 36
More deaths (3% OS rate) were reported in the concurrent arm, but this did not reach statistical significance (RR, 1.60; 0.75–3.44; P = .2).
There was more acute esophagitis (grade 3 or worse) with concurrent treatment (range, 17%–26%) compared with sequential treatment (range, 0%–4%; RR, 6.77; P = .001). Overall, the incidence of neutropenia (grade 3 or worse) was similar in both arms.
Radiation therapy dose escalation for concurrent chemoradiation
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
With improvement in radiation therapy–delivery technology in the 1990s, including tumor-motion management and image guidance, phase I/II trials demonstrated the feasibility of dose-escalation radiation therapy to 74 Gy with concurrent chemotherapy.[41-43] However, a phase III trial of a conventional dose of 60 Gy versus dose escalation to 74 Gy with concurrent weekly carboplatin/paclitaxel did not demonstrate improved local control or PFS, and OS was worse with dose escalation (HR, 1.38; 95% CI, 1.09–1.76; P = .004). There was a nonsignificant increase in grade 5 events with dose escalation (10% vs. 2%) and higher incidence of grade 3 esophagitis (21% vs. 7%; P = .0003). Thus, there is no clear benefit in radiation dose escalation beyond 60 Gy for stage III NSCLC.[44][Level of evidence A1]
Sources: 41 · 43 · 44 · Level of evidence A1
Consolidation therapy following concurrent chemoradiation
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Evidence (consolidation therapy following concurrent chemoradiation):
The randomized phase III PROCLAIM study [NCT00686959] enrolled 598 patients with newly diagnosed, stage IIIA/B, unresectable, nonsquamous NSCLC.[45] Patients were randomly assigned on a 1:1 ratio to either of two arms: The primary objective was OS. The study was designed as a superiority trial with 80% power to detect an OS HR of 0.74 with a type 1 error of .05. This study randomly assigned 598 patients (arm A, 301; arm B, 297) and treated 555 patients (arm A, 283; arm B, 272).
The randomized phase III PROCLAIM study [NCT00686959] enrolled 598 patients with newly diagnosed, stage IIIA/B, unresectable, nonsquamous NSCLC.[45] Patients were randomly assigned on a 1:1 ratio to either of two arms: The primary objective was OS. The study was designed as a superiority trial with 80% power to detect an OS HR of 0.74 with a type 1 error of .05. This study randomly assigned 598 patients (arm A, 301; arm B, 297) and treated 555 patients (arm A, 283; arm B, 272).
Arm A: Pemetrexed (500 mg/m2) and cisplatin (75 mg/m2) intravenously every 3 weeks for three cycles plus concurrent thoracic radiation therapy (60 to 66 Gy) followed by pemetrexed consolidation every 3 weeks for four cycles.
Arm B: Standard therapy with etoposide (50 mg/m2) and cisplatin (50 mg/m2) intravenously every 4 weeks for two cycles plus concurrent thoracic radiation therapy (60 to 66 Gy) followed by two cycles of consolidation platinum-based doublet chemotherapy.
Enrollment was stopped early because of futility.
OS in arm A was not superior to arm B (HR, 0.98; 95% CI, 0.79–1.20; median, 26.8 vs. 25.0 months; P = .831).
Arm A had a significantly lower incidence of any drug-related grade 3 to 4 adverse events (64.0% vs. 76.8%; P = .001), including neutropenia (24.4% vs. 44.5%; P < .001), during the overall treatment period.
Consolidation immunotherapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Durvalumab
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Durvalumab is a selective human IgG1 monoclonal antibody that blocks PD-L1 binding to programmed death 1 (PD-1) and CD80, allowing T cells to recognize and kill tumor cells.[46]
Sources: 46
Evidence (durvalumab following concurrent chemoradiation):
The phase III PACIFIC trial (NCT02125461) enrolled 713 patients with stage III NSCLC whose disease had not progressed after two or more cycles of platinum-based chemoradiation therapy. Patients were randomly assigned in a 2:1 ratio to receive durvalumab (10 mg/kg intravenously) or placebo (every 2 weeks for up to 12 months).[46]
The phase III PACIFIC trial (NCT02125461) enrolled 713 patients with stage III NSCLC whose disease had not progressed after two or more cycles of platinum-based chemoradiation therapy. Patients were randomly assigned in a 2:1 ratio to receive durvalumab (10 mg/kg intravenously) or placebo (every 2 weeks for up to 12 months).[46]
At a median follow-up of 34.2 months for all patients and 61.6 months for censored patients, the median OS was 47.5 months for all patients and 29.1 months for censored patients (stratified HR, 0.72; 95% CI, 0.59–0.89). The median PFS was 16.9 months in the durvalumab group and 5.6 months in the placebo group (stratified HR, 0.55; 95% CI, 0.45–0.68).
The estimated 5-year OS rates were 42.9% (95% CI, 38.2%–47.4%) in the durvalumab group and 33.4% (95% CI, 27.3%–39.6%) in the placebo group.[47][Level of evidence A1]
Sources: 47 · Level of evidence A1
The estimated 5-year PFS rates were 33.1% (95% CI, 28.0%–38.2%) in the durvalumab group and 19% (95% CI, 13.6%–25.2%) in the placebo group.
Grade 3 or 4 adverse events occurred in 29.9% of patients treated with durvalumab and in 26.1% of patients treated with placebo. The most common adverse event of grade 3 or 4 was pneumonia in 4.4% of the patients who received durvalumab and in 3.8% of the patients who received placebo.
Osimertinib (for patients with EGFR variants)
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Evidence (osimertinib following concurrent chemoradiation therapy):
The phase III, double-blind, placebo-controlled LAURA trial (NCT03521154) included patients with unresectable stage III NSCLC and EGFR variants. Patients had not progressed during or after definitive chemoradiation therapy. A total of 216 patients who had undergone chemoradiation therapy were randomly assigned to receive either osimertinib (n = 143) or placebo (n = 73). The primary end point was PFS as assessed by blinded independent central review.[48]
The phase III, double-blind, placebo-controlled LAURA trial (NCT03521154) included patients with unresectable stage III NSCLC and EGFR variants. Patients had not progressed during or after definitive chemoradiation therapy. A total of 216 patients who had undergone chemoradiation therapy were randomly assigned to receive either osimertinib (n = 143) or placebo (n = 73). The primary end point was PFS as assessed by blinded independent central review.[48]
The median PFS was 39.1 months with osimertinib and 5.6 months with placebo (HRdisease progression or death, 0.16; 95% CI, 0.10–0.24; P < .001).
At 36 months, the OS rate was 84% for patients in the osimertinib group (95% CI, 75%–89%) and 74% for patients in the placebo group (95% CI, 57%–85%) (HRdeath, 0.81; 95% CI, 0.42–1.56; P = .53) (at 20% data maturity).[48][Level of evidence A1]
Sources: 48 · Level of evidence A1
Grade 3 or higher adverse events occurred in 35% of patients in the osimertinib group and 12% of patients in the placebo group. Radiation pneumonitis was reported in 48% of patients in the osimertinib group and 38% of patients in the placebo group.
Other systemic consolidation therapies
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
The addition of induction chemotherapy before concurrent chemotherapy and radiation therapy has not been shown to improve survival.[49][Level of evidence A1]
Sources: 49 · Level of evidence A1
Randomized trials of other consolidation systemic therapies, including docetaxel,[50] gefitinib,[51] and tecemotide (MUC1 antigen-specific immunotherapy) [52] have not shown an improvement in OS.[Level of evidence A1]
Sources: 50 · 51 · 52 · Level of evidence A1
Radiation therapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Locally advanced unresectable tumors
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Radiation therapy alone may provide benefit to patients with locally advanced unresectable stage IIIA NSCLC.
Radiation therapy with traditional dose and fractionation schedules (1.8–2.0 Gy per fraction per day to 60–70 Gy in 6–7 weeks) results in reproducible long-term survival benefit in 5% to 10% of patients and significant palliation of symptoms.[53]
Sources: 53
Evidence (radiation therapy for locally advanced unresectable tumor):
One prospective randomized clinical study showed the following:[54]
Sources: 54
One prospective randomized clinical study showed the following:[54]
Radiation therapy given continuously (including weekends) as three daily fractions (continuous hyperfractionated accelerated radiation therapy) improved OS compared with radiation therapy given as one daily fraction.[54][Level of evidence A1]
Sources: 54 · Level of evidence A1
Patterns of failure for patients treated with radiation therapy alone included both locoregional and distant failures.
Although patients with unresectable stage IIIA disease may benefit from radiation therapy, long-term outcomes have generally been poor because of local and systemic relapse.
Palliative treatment
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Radiation therapy may be effective in palliating symptomatic local involvement with NSCLC, such as:
Tracheal, esophageal, or bronchial compression.
Pain.
Vocal cord paralysis.
Hemoptysis.
Superior vena cava syndrome.
In some cases, endobronchial laser therapy and/or brachytherapy has been used to alleviate proximal obstructing lesions.[55]
Sources: 55
Evidence (radiation therapy for palliative treatment):
A systematic review identified six randomized trials of high-dose rate endobronchial brachytherapy (HDREB) alone or with external-beam radiation therapy (EBRT) or laser therapy.[56]
Sources: 56
A systematic review identified six randomized trials of high-dose rate endobronchial brachytherapy (HDREB) alone or with external-beam radiation therapy (EBRT) or laser therapy.[56]
Better overall symptom palliation and fewer re-treatments were required in previously untreated patients using EBRT alone.[56][Level of evidence A3]
Sources: 56 · Level of evidence A3
Although EBRT is frequently prescribed for symptom palliation, there is no consensus about when the fractionation scheme should be used.
For EBRT, different multifraction regimens appear to provide similar symptom relief;[57-62] however, single-fraction radiation therapy may be insufficient for symptom relief compared with hypofractionated or standard regimens, as seen in the NCIC Clinical Trials Group trial (NCT00003685).[59][Level of evidence A3]
Sources: 57 · 62 · NCT00003685 · 59 · Level of evidence A3
Evidence of a modest increase in survival in patients with better performance status given high-dose EBRT is available.[57,58][Level of evidence A1]
Sources: 57 · 58 · Level of evidence A1
HDREB provided palliation of symptomatic patients with recurrent endobronchial obstruction previously treated by EBRT, when it was technically feasible.
Treatment Options for Superior Sulcus Tumors
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Treatment options for superior sulcus tumors include:
Surgery.
Sources: Surgery
Chemoradiation therapy followed by surgery.
Radiation therapy alone.
Sources: Radiation therapy alone
NSCLC of the superior sulcus, frequently termed Pancoast tumors, occurs in less than 5% of patients.[63,64] Superior sulcus tumors usually arise from the apex of the lung and are challenging to treat because of their proximity to structures at the thoracic inlet. At this location, tumors may invade the parietal pleura, chest wall, brachial plexus, subclavian vessels, stellate ganglion, and adjacent vertebral bodies. However, Pancoast tumors are amenable to curative treatment, especially in patients with T3, N0 disease.
Adverse prognostic factors include the presence of mediastinal nodal metastases (N2 disease), spine or subclavian-vessel involvement (T4 disease), and limited resection (R1 or R2).
Surgery
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Evidence (surgery):
Retrospective case series have reported that complete resection was achieved in only 64% of T3, N0 tumors and 39% of T4, N0 tumors.[65]
Sources: 65
Chemoradiation therapy followed by surgery
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Evidence (chemoradiation therapy):
Two large, prospective, multicenter phase II trials have evaluated induction chemoradiation therapy followed by resection.[66,67]
Two large, prospective, multicenter phase II trials have evaluated induction chemoradiation therapy followed by resection.[66,67]
In the first trial (NCT00002642), 110 eligible patients were enrolled with mediastinoscopy negative, clinical T3–4, N0–1 tumors of the superior sulcus.[67] Induction treatment was two cycles of etoposide and cisplatin with 45 Gy of concurrent radiation therapy.
Sources: NCT00002642 · 67
Two large, prospective, multicenter phase II trials have evaluated induction chemoradiation therapy followed by resection.[66,67] › In the first trial (NCT00002642), 110 eligible patients were enrolled with mediastinoscopy negative, clinical T3–4, N0–1 tumors of the superior sulcus.[67] Induction treatment was two cycles of etoposide and cisplatin with 45 Gy of concurrent radiation therapy.
The induction regimen was well tolerated, and only five participants had grade 3 or higher toxic effects.
Induction chemoradiation therapy could sterilize the primary lesion. Induction therapy was completed by 104 patients (95%). Of the 95 patients eligible for surgery, 88 (80%) underwent thoracotomy, two (1.8%) died postoperatively, and 83 (76%) had complete resections.
Pathological complete response or minimal microscopic disease was seen in 61 (56%) resection specimens. Pathological complete response led to better survival than when any residual disease was present (P = .02).
Five-year survival was 44% for all patients and 54% after complete resection, with no difference between T3 and T4 tumors. Disease progression occurred mainly in distant sites.
Two large, prospective, multicenter phase II trials have evaluated induction chemoradiation therapy followed by resection.[66,67]
In the second trial, 75 patients were enrolled and treated with induction therapy with mitomycin C, vindesine, and cisplatin combined with 45 Gy of radiation therapy.[66] Fifty-seven patients (76%) underwent surgical resection, and complete resection was achieved in 51 patients (68%).
Sources: 66
Two large, prospective, multicenter phase II trials have evaluated induction chemoradiation therapy followed by resection.[66,67] › In the second trial, 75 patients were enrolled and treated with induction therapy with mitomycin C, vindesine, and cisplatin combined with 45 Gy of radiation therapy.[66] Fifty-seven patients (76%) underwent surgical resection, and complete resection was achieved in 51 patients (68%).
There were 12 patients with pathological complete response.
Major postoperative morbidity, including chylothorax, empyema, pneumonitis, adult respiratory distress syndrome, and bleeding, was observed in eight patients. There were three treatment-related deaths.
At 3 years, the DFS rate was 49%, and the OS rate was 61%; at 5 years, the DFS rate was 45%, and the OS rate was 56%.[66][Level of evidence C2]
Sources: 66 · Level of evidence C2
Radiation therapy dose escalation for concurrent chemoradiation
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
With improvement in radiation therapy–delivery technology in the 1990s, including tumor-motion management and image guidance, phase I/II trials demonstrated the feasibility of dose-escalation radiation therapy to 74 Gy with concurrent chemotherapy.[41-43] However, a phase III trial of a conventional dose of 60 Gy versus dose escalation to 74 Gy with concurrent weekly carboplatin/paclitaxel did not demonstrate improved local control or PFS, and OS was worse with dose escalation (HR, 1.38 [1.09–1.76]; P = .004). There was a nonsignificant increase in grade 5 events with dose escalation (10% vs. 2%) and higher incidence of grade 3 esophagitis (21% vs. 7%; P = .0003). Thus, there is no clear benefit in radiation dose escalation beyond 60 Gy for stage III NSCLC.[44][Level of evidence A1]
Sources: 41 · 43 · 44 · Level of evidence A1
Radiation therapy alone
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
While radiation therapy is an integral part of the treatment of Pancoast tumors, variations in dose, treatment technique, and staging that were used in various published series make it difficult to determine its effectiveness.[63,64]
Small, retrospective series of radiation therapy in patients who were only clinically staged have reported 5-year survival rates of 0% to 40%, depending on T stage, total radiation dose, and other prognostic factors. Induction radiation therapy and en bloc resection was shown to be potentially curative.
Evidence (radiation therapy):
Treatment Options for Tumors That Invade the Chest Wall
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Treatment options for tumors that invade the chest wall include:
Surgery.
Surgery and radiation therapy.
Radiation therapy alone.
Chemotherapy combined with radiation therapy and/or surgery.
Selected patients with bulky primary tumors that directly invade the chest wall can obtain long-term survival with surgical management provided that their tumor is completely resected.
Evidence (radical surgery):
In a small case series of 97 patients, the 5-year survival rate of patients who had completely resected T3, N0, M0 disease was 44.2%. For patients with completely resected T3, N1, M0 disease, the 5-year survival rate was 40.0%. In patients with completely resected T3, N2, M0 disease, the 5-year survival rate was 6.2%.[68][Level of evidence C2]
Sources: 68 · Level of evidence C2
In a small case series of 104 patients, the 5-year survival rate of patients who had completely resected T3, N0, M0 disease was 67.3%. For patients with completely resected T3, N1, M0 disease, the 5-year survival rate was 100.0%. In patients with completely resected T3, N2, M0 disease, the 5-year survival rate was 17.9%.[69][Level of evidence C2]
Sources: 69 · Level of evidence C2
In a case series of 309 patients treated at three centers, patients who underwent en bloc resection had superior outcomes compared with patients who underwent extrapleural resections (60.3% vs. 39.1%; P = .03).[70][Level of evidence C2]
Sources: 70 · Level of evidence C2
Adjuvant chemotherapy is recommended, and radiation therapy is reserved for cases with unclear resection margins. Survival rates were lower in patients who underwent incomplete resection and had mediastinal lymph node involvement. Combined-modality approaches have been evaluated to improve ability to achieve complete resection.
Treatment of Stages IIIB and IIIC NSCLC
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
On the basis of the Surveillance, Epidemiology, and End Results (SEER) Program registry, the estimated incidence of stage IIIB non-small cell lung cancer (NSCLC) is 17.6%.[1] The anticipated 5-year survival rate for most patients who present with clinical stage IIIB NSCLC is 3% to 7%.[2] In small case series, selected patients with T4, N0–1 disease, solely as the result of satellite tumor nodule(s) within the primary lobe, had 5-year survival rates of 20%.[3,4][Level of evidence C1]
Sources: stage IIIB non-small cell lung cancer (NSCLC) · 1 · 2 · 3 · 4 · Level of evidence C1
Treatment Options for Stages IIIB and IIIC NSCLC
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Treatment options for stages IIIB NSCLC and IIIC NSCLC include:
Sources: stages IIIB NSCLC · IIIC NSCLC
Sequential or concurrent chemotherapy and radiation therapy.
Sources: Sequential or concurrent chemotherapy and radiation therapy
Sequential or concurrent chemotherapy and radiation therapy.
Radiation therapy dose escalation for concurrent chemoradiation.
Sources: Radiation therapy dose escalation for concurrent chemoradiation
Systemic consolidation therapy before or after concurrent chemoradiation therapy.
Sources: Systemic consolidation therapy before or after concurrent chemoradiation therapy
Sequential or concurrent chemotherapy and radiation therapy. › Systemic consolidation therapy before or after concurrent chemoradiation therapy.
Consolidation immunotherapy.
Sources: Consolidation immunotherapy
Other systemic consolidation therapies.
Radiation therapy alone.
Sources: Radiation therapy alone
Radiation therapy alone.
For treatment of locally advanced unresectable tumor in patients who are not candidates for chemotherapy.
For patients requiring palliative treatment.
New fractionation schedules (under clinical evaluation).
Radiosensitizers (NCT02186847) (under clinical evaluation).
Sources: NCT02186847
Combined-modality approaches (under clinical evaluation).
Incorporation of targeted agents into combined modality therapy in patients with EGFR variants or ALK translocations (RTOG-1306 [NCT01822496]; 11-464 [NCT01553942]) (under clinical evaluation).
Sources: NCT01822496 · NCT01553942
Adaptive radiation therapy using positron emission tomography–based response assessment during treatment (RTOG-1106/ACRIN-6697) (under clinical evaluation).
Sources: RTOG-1106/ACRIN-6697
In general, patients with stages IIIB and IIIC NSCLC do not benefit from surgery alone and are best managed by initial chemotherapy, chemotherapy plus radiation therapy, or radiation therapy alone, depending on:
Sites of tumor involvement.
The patient's performance status.
Most patients with excellent performance status are candidates for combined-modality chemotherapy and radiation therapy with the following exceptions:
Selected patients with T4, N0 disease may be treated with combined-modality therapy and surgery similar to patients with superior sulcus tumors.
Patients with stages IIIB or IIIC NSCLC are candidates for clinical trials, which may lead to improvement in the control of disease.
Sequential or concurrent chemotherapy and radiation therapy
Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 15, 2025. Captured 2026-09-09.
Many randomized studies of patients with unresectable stage III NSCLC show that treatment with preoperative or concurrent cisplatin-based chemotherapy and radiation therapy to the chest is associated with improved survival compared with treatment that uses radiation therapy alone. Although patients with unresectable stages IIIB or IIIC disease may benefit from radiation therapy, long-term outcomes have generally been poor, often the result of local and systemic relapse. The addition of sequential and concurrent chemotherapy to radiation therapy has been evaluated in prospective randomized trials.
Evidence (sequential or concurrent chemotherapy and radiation therapy):
A meta-analysis of patient data from 11 randomized clinical trials showed the following:[5]
Sources: 5
A meta-analysis of patient data from 11 randomized clinical trials showed the following:[5]
Cisplatin-based combinations plus radiation therapy resulted in a 10% reduction in the risk of death compared with radiation therapy alone.[5][Level of evidence A1]
Sources: 5 · Level of evidence A1
A meta-analysis of 13 trials (based on 2,214 evaluable patients) showed the following:[6]
Sources: 6
A meta-analysis of 13 trials (based on 2,214 evaluable patients) showed the following:[6]
The addition of concurrent chemotherapy to radical radiation therapy reduced the risk of death at 2 years (relative risk [RR], 0.93; 95% confidence interval [CI], 0.88–0.98; P = .01).
For the 11 trials with platinum-based chemotherapy, RR was 0.93 (95% CI, 0.87–0.99; P = .02).[6]
Sources: 6
A meta-analysis of individual data from 1,764 patients evaluated nine trials.[7]
Sources: 7
A meta-analysis of individual data from 1,764 patients evaluated nine trials.[7]
The hazard ratio (HR)death among patients treated with radiation therapy and chemotherapy compared with radiation therapy alone was 0.89 (95% CI, 0.81–0.98; P = .02) corresponding to an absolute benefit of chemotherapy of 4% at 2 years.
The combination of platinum with etoposide appeared to be more effective than platinum alone. Concomitant platinum-based chemotherapy and radiation therapy may improve survival of patients with locally advanced NSCLC. However, the available data are insufficient to accurately define the size of such a potential treatment benefit and the optimal schedule of chemotherapy.[7]
Sources: 7
The results from two randomized trials (including RTOG-9410 [NCT01134861]) and a meta-analysis indicate that concurrent chemotherapy and radiation therapy provide greater survival benefit, albeit with more toxic effects, than sequential chemotherapy and radiation therapy.[8-10][Level of evidence A1]
Sources: RTOG-9410 · 8 · 10 · Level of evidence A1
The results from two randomized trials (including RTOG-9410 [NCT01134861]) and a meta-analysis indicate that concurrent chemotherapy and radiation therapy provide greater survival benefit, albeit with more toxic effects, than sequential chemotherapy and radiation therapy.[8-10][Level of evidence A1]
In the first trial, the combination of mitomycin C, vindesine, and cisplatin were given concurrently with split-course daily radiation therapy to 56 Gy compared with chemotherapy followed by continuous daily radiation therapy to 56 Gy.[8]
Sources: 8
The results from two randomized trials (including RTOG-9410 [NCT01134861]) and a meta-analysis indicate that concurrent chemotherapy and radiation therapy provide greater survival benefit, albeit with more toxic effects, than sequential chemotherapy and radiation therapy.[8-10][Level of evidence A1] › In the first trial, the combination of mitomycin C, vindesine, and cisplatin were given concurrently with split-course daily radiation therapy to 56 Gy compared with chemotherapy followed by continuous daily radiation therapy to 56 Gy.[8]
Five-year overall survival (OS) rates favored concurrent therapy (27% vs. 9%).
Myelosuppression was greater among patients in the concurrent arm, but treatment-related mortality was less than 1% in both arms.[8]
Sources: 8
The results from two randomized trials (including RTOG-9410 [NCT01134861]) and a meta-analysis indicate that concurrent chemotherapy and radiation therapy provide greater survival benefit, albeit with more toxic effects, than sequential chemotherapy and radiation therapy.[8-10][Level of evidence A1]
In the second trial, 610 patients were randomly assigned to sequential chemotherapy with cisplatin and vinblastine followed by 63 Gy of radiation therapy, concurrent chemoradiation therapy using the same regimen, or concurrent chemotherapy with cisplatin and etoposide with twice-daily radiation therapy.[9,10]
The results from two randomized trials (including RTOG-9410 [NCT01134861]) and a meta-analysis indicate that concurrent chemotherapy and radiation therapy provide greater survival benefit, albeit with more toxic effects, than sequential chemotherapy and radiation therapy.[8-10][Level of evidence A1] › In the second trial, 610 patients were randomly assigned to sequential chemotherapy with cisplatin and vinblastine followed by 63 Gy of radiation therapy, concurrent chemoradiation therapy using the same regimen, or concurrent chemotherapy with cisplatin and etoposide with twice-daily radiation therapy.[9,10]
Median and 5-year survival were superior in the concurrent chemotherapy with daily radiation therapy arm (17 months vs. 14.6 months and 16% vs. 10% for sequential regimen [P = .046]).
The results from two randomized trials (including RTOG-9410 [NCT01134861]) and a meta-analysis indicate that concurrent chemotherapy and radiation therapy provide greater survival benefit, albeit with more toxic effects, than sequential chemotherapy and radiation therapy.[8-10][Level of evidence A1]
Two smaller studies also reported OS results that favored concurrent over sequential chemotherapy and radiation, although the results did not reach statistical significance.[10][Level of evidence A1]; [11]
Sources: 10 · Level of evidence A1 · 11
A meta-analysis of three trials evaluated concurrent versus sequential treatment (711 patients).[6]
Sources: 6
A meta-analysis of three trials evaluated concurrent versus sequential treatment (711 patients).[6]
The analysis indicated a significant benefit of concurrent versus sequential treatment (RR, 0.86; 95% CI, 0.78–0.95; P = .003). All used cisplatin-based regimens and once-daily radiation therapy.[6]
Sources: 6
More deaths (3% overall) were reported in the concurrent arm, but this did not reach statistical significance (RR, 1.60; 0.75–3.44; P = .2).
There was more acute esophagitis (grade 3 or worse) with concurrent treatment (range, 17%–26%) compared with sequential treatment (range, 0%–4%; RR, 6.77; P = .001). Overall, the incidence of neutropenia (grade 3 or worse) was similar in both arms.
Triangle